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I. INTRODUCTION 
Before going into detail of the purpose and the need of laboratory animal models, 
it should be clarified how to define this term. One example for defining gives the 
U.S. National Research Committee on Animal Models for Research on Aging, 
which reads as follows: ―an animal model in which normative biology or behavior 
can be studied, or in which a spontaneous or induced pathological process can be 
investigated, and in which the phenomenon in one or more respects resembles the 
same phenomenon in humans or other species of animal‖. Most of the times when 
the term ―animal model‖ is used, the true meaning is modeling humans. 
Consequently it would be more correct to speak of ―human model‖ on this 
context. Recently, just as well as in the past 150 years, the majority of laboratory 
animal models are developed and used to study the cause, nature, and cure of 
human disorders (SVENDSEN & HAU, 1994). The successful development of 
transgenic animal models for human diseases has led to remarkable breakthroughs 
that have a major impact on the diagnosis, treatment and intervention in human 
diseases. Furthermore they have helped to clarify our understanding of disease 
mechanisms, as well as the onset and course of disease pathology. Because no 
single animal model meets all necessary requirements to exactly mimic the human 
circumstances, it is the obligation of researchers to identify the best and most 
appropriate animal model that is adequate for a specific study (CHAN, 2004; 
CHAN & YANG, 2009). The question is which animal on the one hand fits best 
these requirements of modeling the human conditions and on the other hand is 
feasible in financial and practical terms. In the long period of domestication, 
presumably 9000 years (LARSON et al., 2005), the pig was not only selected for 
meat quality but also for high fertility. The pig is used as a livestock species in 
most parts of the world and people accept killing of swine for human nutrition. 
Livestock pig breeds and miniature pig breeds are already commonly used in 
various fields of research. In human medicine they are used for different purposes 
for example in surgery, internal medicine, nutritional medicine and infectious 
diseases (SMITH & SWINDLE, 2006; LUNNEY, 2007). Pigs are contributing 
not only to research but also to therapy: bioprostetic heart valves originating from 
pigs are commercially available and routinely used for transplantation to human 
patients (BROWN et al., 2009). Through this long time of experience in usage of 
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pig in the laboratory many technical procedures have been already established, 
like for example pig handling, husbandry, anesthesia, analgesia and perioperative 
care, and are now available for non-transgenic and transgenic pig models. 
Reproductive technology and techniques of genetic modifications have 
considerably advanced in the last years (WOLF et al., 2000; HOUDEBINE, 
2005). In contrast to traditional laboratory animals like rodents, pigs have a 
relatively long lifespan and are more similar to humans concerning their organ 
size, anatomy and physiology (VAJTA et al., 2007). Especially for chronic 
diseases, where it will take years until the specific phenotype will show, a long 
lived animal model is needed. For all these reasons our choice fell on the pig to 
establish a transgenic animal model for human osteoporosis, based on osteoclast 
deregulation. The excessive resorption of bone tissues should be stimulated by a 
regulated expression of RANKL (receptor-activator of nuclear factor kappa beta 
ligand). One major limitation in transgenic pig production is the efficiency in 
somatic cell nuclear transfer. Most of the transferred SCNT embryos do not 
develop full term, so that the number of born transgenic SCNT piglets still is quite 
low (VAJTA et al., 2007; KEEFER, 2008). The subject of this thesis was the 
elucidation of the generation process of transgenic pigs via SCNT exemplified by 
the generation of RANKL transgenic pigs. Nuclear transfer and embryo transfer 
data from our laboratory of the years 2006 until 2010 were examined to identify 
additional features that influence overall SCNT efficiency. As an essential part of 
the DFG research group ―Mechanisms of fracture healing and bone regeneration 
in osteoporosis‖ (DFG 793/ project 2: http://ufbweb.medizin.uni-ulm.de/dfg793/), 
this project created the basis for the first transgenic large animal model for 
osteoporosis, which will be used for fracture healing studies by other research 
group partners.  
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II. LITERATURE 
1. Osteoporosis in general 
1.1. Pathophysiology of osteoporosis 
1.1.1. Definition  
The chronic skeletal disorder osteoporosis is described by low bone mass and 
microarchitectural deterioration of bone tissue, which leads to an increased 
fracture risk (REINWALD & BURR, 2008; RAHMANI & MORIN, 2009). The 
World Health Organization (WHO) defines osteoporosis in humans as a bone 
mineral density that is 2.5 standard deviations (SD) below the mean value of 
healthy young adults (T-score) (EGERMANN et al., 2005; SIPOS et al., 2009). 
Additionally, osteoporosis changes the course of fracture healing in terms of 
diminished amount and speed of callus formation (EGERMANN et al., 2005).  
The homeostasis of bone formation is disturbed through either too much 
absorption or too less build-up of bone tissue.  
1.1.2. Bone remodeling  
The most important cell types of bone are osteoblasts and osteoclasts. In the organ 
system bone, there is a life-long state of repairing, adapting bone constitution and 
maintaining calcium and phosphorus level (KEARNS et al., 2008; WRIGHT et 
al., 2009). Bone homeostasis is maintained by a balance between bone-forming 
cells, the osteoblasts, and bone-resorbing cells, the osteoclasts (NANES & 
KALLEN, 2009). Osteoclasts are derived from hematopoietic progenitors, 
whereas osteoblasts differentiate from mesenchymal stem cells. In a physiological 
state there is a balance between activity of osteoblast and osteoclast cells, but in 
osteoporotic patients this balance is disturbed. This balance is regulated through 
various hormones and cytokines. Complete osteoclastogenesis and osteoclast 
activity can only be performed if RANKL is present (YAVROPOULOU & 
YOVOS, 2008). 
1.1.3. Clinical aspects  
There is a clear relationship between aging and the incidence of osteoporosis. 
Women are affected more often than men, due to the postmenopausal estrogen 
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deficiency (RAHMANI & MORIN, 2009; SIPOS et al., 2009). Typically the 
disease proceeds without any clinical symptoms and doesn’t become apparent 
until a bone fracture occurs. Screening for individual fracture risk is still not 
feasible in usual clinical settings. To estimate the progression of the disease, the 
following factors have to be taken into account: bone architecture and geometry, 
mineralization, microdamage accumulation, and properties of the collagen and 
mineral matrix (NANES & KALLEN, 2009). Around the age of 30 years adult 
people reach their peak bone mass, and then bone density continues to fall in both 
sexes, with loss accelerating in women after menopause. The rate of loss is similar 
in older men and postmenopausal women (NANES & KALLEN, 2009). Physical 
activity has a major impact on incidence of osteoporosis. Weight and bone mass 
index are strongly aligned to bone mineral density in women and elderly men. 
Additionally weight affects bone mineral density as a load factor (FELSON et al., 
1993). Dietary patterns and especially protein intake as well have an impact on 
bone mineral density (HANNAN et al., 2000; TUCKER et al., 2002).  
1.1.4. Classification  
There is a basic classification into primary and secondary osteoporosis. The 
primary form shows in a decrease of bone mineral density during the course of 
aging and the subsequent sex hormone changes. Bone loss in primary osteoporosis 
is caused by estrogen deficiency in postmenopausal women and aging men (senile 
osteoporosis) (SIPOS et al., 2009). Most frequently the cause of secondary 
osteoporosis is glucocorticoid medication. But there are also a variety of medical 
conditions and other medications that can affect bone turnover. Prevalently 
primary osteoporosis holds the biggest fraction of all cases (BONURA, 2009).  
1.1.5. Fragility fractures and health risk  
A normal human being ought to be able to fall from standing height without 
breaking bones, therefore a fragility fracture indicates pathologic weakness of the 
skeleton (NANES & KALLEN, 2009). Epidemiological studies showed that 2 
million fractures or even more occurred every year in the United States caused by 
osteoporosis (BURGE et al., 2007; NANES & KALLEN, 2009). After a fragility 
fracture, caused by osteoporosis, the risk of subsequent fractures is significantly 
elevated. The study accomplished by Bliuc et al. demonstrated that there is an 
increased mortality following all major types of osteoporosis related fractures and 
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even after minor fractures with older age. Mortality risk was highest in the first 5 
years following all types of fractures (BLIUC et al., 2009). Especially hip 
fractures had a fatal follow-up, which displayed in mobility loss that most of the 
times will never fully reach previous status and finally ended in the requirement 
of long term care (BONURA, 2009).  
1.2. Economic burden 
The prominence of osteoporosis is expected to increase rapidly in the close future, 
because of the demographic changes. The group of Häussler et al. examined cases 
of osteoporosis during the year 2003 in Germany. They calculated the total direct 
cost resulting from osteoporosis and the outcome was 5.4 billion Euros. They also 
estimated the average cost of an osteoporotic patient with a fracture to 9962 Euro 
and to 281 Euro without a fracture. The Central Bureau of Statistics in Germany 
figured that about 4 to 6 million people are affected by osteoporosis. It was 
predicted that in the year 2013 the number of patients will grow up to 990 million 
persons. The study shows that osteoporosis imposes a considerable economic 
burden for the healthcare system in Germany (HAUSSLER et al., 2007). In the 
United States costs to the health care system aligned to osteoporosis and related 
fractures were estimated at $17 billion in the year 2005 (BURGE et al., 2007; 
BONURA, 2009). This setting is probably due to impaired fracture healing in the 
osteoporotic bone, leading to an increased failure rate of implant fixation. There 
have been reported failure rates of up to 50% for osteoporotic patients, mostly due 
to a pull-out or cut-through phenomenon (EGERMANN et al., 2005). 
2. Large animal models for osteoporosis 
2.1. Need for large animal models 
When animal models were applied for the study of osteoporosis some difficulties 
could be sidestepped which occur in human study groups, such as the variability 
seen in both genetic background and environmental influences and the inability to 
obtain human tissues for molecular analysis (LIND & SEMSARIAN, 2006). In 
addition, results of in vitro studies of human tissues can be difficult to extrapolate 
to the in vivo situation (PEARCE et al., 2007). Cell cultures and other in vitro 
assays might help to investigate the reaction of normal and osteoporotic cells 
subsequent to different kinds of stimuli, but they lack the effects of central control 
of bone turnover and the feedback mechanisms involved in physical activity 
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(EGERMANN et al., 2005). One obstacle to the understanding of postmenopausal 
osteoporosis is that this disease is restricted to humans and does not naturally 
occur in other species. Due to the chronically progressive nature of the disease it 
is necessary to employ long-time studies of several years duration, resulting in a 
protracted progress in research. Accordingly, collection of data costs a lot of time 
and preservation of study groups can be very difficult (TURNER, 2001). 
Individual behavior like smoking, alcoholism, inadequate nutrition, and 
insufficient physical activity were reported to have an effect on the incidence of 
osteoporosis (BONURA, 2009). As a consequence creating a homogenous study 
group is problematic and data is impaired by relatively high variance. The gain of 
using an animal model is the availability of more uniform experimental material 
and the possibility of extensive testing of potential therapies. Large animal models 
provide also the possibility of testing new prosthetic devices which than can be 
optimized to fulfill all requirements of the human osteoporotic bone. Drug therapy 
trials and orthopedic implant testing in large animal models can be accomplished 
at a level of experimental control impossible in human clinical research 
(TURNER, 2001). Regulatory guidelines for preclinical evaluation of new 
experimental drug therapies to treat or prevent postmenopausal osteoporosis 
require the use of two species to assess bone safety: the rat, because it is well 
characterized, and a second large long-lived animal model with intracortical bone 
remodeling (THOMPSON et al., 1995; SMITH et al., 2009). The often used 
rodent models have the disadvantage of dissimilar anatomy and physiology of 
bone compared to human, limitation of size, and their short life-span. In 
consequence it is impossible to test human implants, gather greater amount of 
tissue samples, and to perform long-time studies of several years duration 
(PEARCE et al., 2007). Rodents show no intracortical bone remodeling, they lack 
structures as Haversian canals, and they have a different form of fracture healing 
when compared with humans (REINWALD & BURR, 2008).  
2.2. Sheep as animal models 
Adult sheep have a similar body weight to humans and the size of their long bones 
is suitable for human implants and prostheses. It is described that sheep 
predominantly have a primary bone structure on the contrary to humans with 
mainly secondary bones. Sheep also display a notably higher bone density and 
consequently a higher strength when compared to humans (PEARCE et al., 2007). 
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Due to their body size it is possible to implant prosthetics and to obtain large 
amounts of blood and urine samples as well as bone biopsies (SIGRIST et al., 
2007). Older sheep display Haversian bone remodeling (ZARRINKALAM et al., 
2009). Sexual cycles of different sheep breeds are generally seasonally 
polyestrous, but some breeds have an almost continues cycles (e.g. Merino). 
Seasonal changes in the bone density have been observed in the sheep, which 
could be caused by the periods of anestrous linked to the changing photoperiods 
throughout the year (TURNER, 2001). The sheep is a quadruped and herbivore 
animal, which leads to a different physiology when compared with humans 
(REINWALD & BURR, 2008). Aged sheep showed 6 months after ovariectomy 
an 8-10% loss of cortical bone and <1% loss of cancellous bone at the distal tibia 
(LILL et al., 2000; REINWALD & BURR, 2008). Thus in the sheep a maximum 
of 10% bone mass reduction could be achieved through estradiol withdrawal and 
aging, whereas in osteoporotic humans this value is at least fourfold higher 
(ROSS, 1996; SIGRIST et al., 2007). When osteoporosis was induced with 
ovariectomy, additional low calcium diet and steroid injection over 6 months, the 
bone mineral density decreased by more than 25% (ZARRINKALAM et al., 
2009). To study the long-term effects of ovariectomy on bone metabolism, the 
group of Sigrist et al. operated six ewes and observed them over a period of 18 
months. They could show that most of the bone loss (-13%) occurred during the 
first 4 months. Between 7 and 9 months the bone mass appeared to stabilize at the 
mentioned osteopenic level. Afterwards the bone mass returned to pre-
ovariectomy levels and remained at this value for the rest of the study. Further on 
their studies revealed that there was a significant drop of systemic estrogen levels 
after ovariectomy, followed by increasing values until they finally reach again the 
basic level same as the control group. Therefore, it appears that the destructive 
effect of ovariectomy on sheep bone metabolism is a reversible process and the 
standard bone parameters are reestablished within 6 months after surgery 
(SIGRIST et al., 2007). Another approach to reduce the bone volume of sheep 
was achieved through intracerebroventricularly leptin injection. This report 
elucidated that bone remodeling is also regulated by the central nervous system 
(POGODA et al., 2006).   
2.3. Dog as animal models 
Depending on the size and breed of dog, there may be some discrepancy in the 
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size and shape of canine bones in comparison to human bones. While adult human 
bone has a secondary osteonal structure, the canine bone is found to have a mixed 
microstructure of secondary osteonal bone and plexiform bone. Canine bone has a 
significantly higher mineral density than human bone. The rate of bone 
remodeling is different compared with humans (PEARCE et al., 2007). Dogs have 
already been used in studies modeling the human skeletal conditions like for 
example fracture healing, effects of immobilization, long-term effects of certain 
bone-active agents and allografts (TURNER, 2001). Dogs are like the human 
monogastric, but in their sexual cycle they are quite different. Female dogs 
ovulate twice a year and are therefore diestrus. So it appears that dogs have 
unchanged hormone levels during their long lasting periods of anestrus 
(TURNER, 2001). Despite some similarities between human and dog bone, a 
number of researchers remain uncertain of the potential of ovariectomy to induce 
significant bone loss in dogs. Results among laboratories have either differed or 
have been entirely encouraging (REINWALD & BURR, 2008). There is a report 
of beagles showing a 8-10% loss of bone density in the vertebrae in 8 to 12 
months post ovariectomy (DREZNER & NESBITT, 1990). Ovariectomy in dogs 
leaded to either decreased or unchanged cancellous bone volume, whereas bone 
mineral density (BMD) was mostly unchanged. Additionally the fracture rate 
among ovariohysterectomized pet dogs, even in older age, is not comparable to 
those of postmenopausal women (EGERMANN et al., 2005). Although in the 
period of anestrus the levels of estrogen are extremely low, spontaneous fractures 
in dogs are almost unknown. Additionally the routinely removal of both ovaries 
and uterus appealingly does not lead to a major bone loss (TURNER, 2001).  
2.4. Nonhuman primates as animal models 
The nonhuman primate is the most closely related species and therefore the most 
physiologically similar to humans (SMITH et al., 2009). Old World monkeys such 
as baboons and macaques organ system, like the gastrointestinal tract, endocrine 
system and bone metabolism, closely resemble those of humans (NEWMAN et 
al., 1995). Females have a monthly cycle of 28 days and hormonal patterns 
including estrogen and progesterone levels similar to humans. Declining ovarian 
function and irregular menstrual cycles occur in macaques over 20 years and in 
baboons over 15 years of age (EGERMANN et al., 2005). However, spontaneous 
menopause does not occur in most nonhuman primates (NEWMAN et al., 1995). 
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The long life-span of nonhuman primates is also important in bone studies, but on 
the other hand also challenging since cynomolgus monkeys are typically at least 9 
years, and rhesus monkeys at least 12 years old, reflecting the reported age that 
they reach peak bone mass (SMITH et al., 2009). Osteoporosis only occurs 
naturally in humans and nonhuman primates. In a study, rhesus monkeys showed 
a decline in bone density with advancing age and several aged individuals 
developed vertebral wedge fractures (CERRONI et al., 2000, 2003; EGERMANN 
et al., 2005). This report is the only one describing natural occurring osteoporosis 
and spontaneous fractures in animals. Ovariectomy in cynomolgus monkeys lead 
to a bone loss of -1.4 SD compared with healthy control animals (EGERMANN et 
al., 2005). In humans osteoporosis is defined as a BMD 2.5 SD or more under the 
mean value of healthy young adults. In other studies nonhuman primates showed 
a loss of BMD of 3% to 7% from the baseline value 16 to 18 months after 
ovariectomy. They lost bone mass after OVX, but the extent of the bone loss 
cannot be described as osteoporotic (SMITH et al., 2009). Additional strategies, 
like steroid medication or/and calcium low diet, are therefore necessary to induce 
significant bone loss comparable to human osteoporosis patients (EGERMANN et 
al., 2005).  
2.5. Pig as animal models 
Because of the well-characterized and striking anatomical similarities between 
pigs and humans, swine are used in biomedical research as relevant models for 
numerous human conditions and diseases, and have emerged as the preferred 
donor for xenotransplantation (VODICKA et al., 2005; SMITH & SWINDLE, 
2006; LUNNEY, 2007; REINWALD & BURR, 2008). In both species bone 
metabolism is significantly affected by diet and nutrition. Humans and swine are 
both monogastric and true omnivores, so that the gross gastrointestinal 
physiological function of swine is more similar to humans than that of most other 
species (REINWALD & BURR, 2008). Domestic pig shows a rapid growth and 
attains body weights of 150 to 200 kg at maturity. Many authors describe pig as 
noisy and stubborn or even aggressive animal. Pigs are social and intelligent 
animals and, when handled and housed correctly, aggression problems are less 
likely encountered (SMITH & SWINDLE, 2006; REINWALD & BURR, 2008). 
The sexual cycle of the pig is quite similar to that of human and it is continuous 
throughout all seasons. In contrary to humans the pigs are quadrupeds and 
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therefore have different weight distributions. Their size permits the introduction 
of prosthetic implants and also it is possible to apply repetitive bone biopsies and 
to obtain large amounts of blood samples (NEWMAN et al., 1995). With regard to 
bone anatomy, morphology, healing and remodeling, the pig bone is considered to 
be closely representative of human bone. While having a denser trabecular 
network, the pig has a human like lamellar bone structure. Pigs have a similar rate 
of bone regeneration and cortical bone mineralization to humans (PEARCE et al., 
2007). There is a close similarity of bone remodeling rates of pigs and humans 
and an overlap in Haversian canal diameters and secondary osteon dimensions 
among humans and pigs (REINWALD & BURR, 2008). Swine reach their peak 
bone mass at the age of 2.5 to 3 years, thereafter their bone mineral density begins 
to drop (TURNER, 2001). They are one of the few species where spontaneous 
vertebral fractures have been reported. These fractures occurred after pregnancy 
and during the lactation period, a disease that could be termed ―porcine lactational 
osteoporosis‖ (SPENCER, 1979). Ovariectomy of sows did not significantly 
affect the variables of bone chemical and histological analyses (SCHOLZ-
AHRENS et al., 1996). In Sinclair minipigs a (0.75%) calcium restricted diet in 
combination with ovariectomy resulted in a 7-10% reduction in spinal bone 
mineral density (BOYCE et al., 1995). Glucocorticosteroid-induced osteoporosis 
in adult Göttingen miniature pigs lead to bone mineral density depression of -10% 
from baseline. In the long term a slight further decline of 1% was observed 
(SCHOLZ-AHRENS et al., 2007).  
2.6. Comparing different large animal models 
Surely most similarities are found between old world monkeys and humans, but 
legal restrictions and housing conditions for the animals often create public 
distaste for their use. These ethical concerns and the relatively high risk of 
zoonotic disease transmission makes this model inconvenient (TURNER, 2001). 
In addition, housing and handling are demanding and therefore expensive, 
especially because the monkeys have to reach a certain age before they can be 
used (NEWMAN et al., 1995). It has to be taken into account that, in an economic 
climate, where financial resources for research are becoming increasingly limited, 
the choice of experimental animals must be scientifically and ethically justifiable 
as well as cost-effective (REINWALD & BURR, 2008). The second best model 
resembling the human physiological conditions, especially in the bone, is the 
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porcine large animal model (see table below) (PEARCE et al., 2007; REINWALD 
& BURR, 2008). Dogs or monkeys provoke emotional attachments and are 
individualized unlike farm animals as pigs or sheep (TURNER, 2001). Although 
osteoporosis can be induced in several animal models, spontaneous fractures 
without adequate trauma were only found in nonhuman primates. Ovariectomy 
alone seems to be adequate to reduce the mechanical properties of bone but does 
not reduce bone mineral density to levels comparable with those seen in 
osteoporotic human patients. Models using steroid medication combined with 
ovariectomy and calcium-wasting diet show the most severe bone loss 
(EGERMANN et al., 2005). Another limitation of osteoporosis animal models is 
that commonly female individuals were utilized for trials and the osteoporotic 
conditions in the senile male are overlooked. All of the animal models presented 
above have certain differences from humans and it is not yet proven that they 
accurately resemble the situation found in osteoporotic patients (TURNER, 2001). 
Today there is no truly satisfying large animal model for osteoporosis at hand 
(REINWALD & BURR, 2008). Future investigations must address the finding 
that the elimination of ovarian function does not always lead to osteoporosis and a 
high risk of fracture (EGERMANN et al., 2005).  
Table 1: Summary of four key attributes in terms of similarity between 
animal and human bone (PEARCE et al., 2007) 
 Canine Sheep/Goat Pig Rabbit 
Macrostructure ++ +++ ++ + 
Microstructure ++ + ++ + 
Bone 
Composition 
+++ ++ +++ ++ 
Bone 
Remodelling 
++ ++ +++ + 
+ least similar, ++ moderately similar, +++ most similar 
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3. Relevance of RANKL in health and disease 
3.1. Role of RANKL/RANK/OPG system in bone remodeling 
3.1.1. RANKL/RANK/OPG signaling  
The discovery of the RANKL/RANK/OPG system in the late 1990s greatly 
improved the understanding of bone remodeling and maintenance of the skeletal 
structure (BOYCE & XING, 2008; WRIGHT et al., 2009). Three key proteins are 
responsible for the regulation process of bone resorption: RANK (receptor-
activator of nuclear factor kappa beta), its ligand RANKL (receptor-activator of 
nuclear factor kappa beta ligand) and a decoy receptor OPG (osteoprotegerin). 
This system is controlled by many osteotropic hormones (parathyroid hormone 
(PTH), 1,25dihydroxyvitaminD3 (Vitamin D3a), prostaglandin E2 (PG E2), 
estrogen, testosterone and prolactin) and cytokines (inflammatory cytokines e.g. 
interleukines: IL-1α, IL-1β, IL-6b, IL-11 and IL-17), tumor necrosis factor alpha 
and beta (TNFα and TNFβ) and transforming growth factor beta (TGF-β)) 
(WRIGHT et al., 2009). Osteoclasts’ number and activity are closely dependent 
on the ratio of RANKL/OPG and every change in this ratio will have an effect on 
bone turnover (BOYCE & XING, 2008). The RANK/RANKL/OPG signaling 
system is essential for skeletal homeostasis and plays a major role in most animal 
models of bone diseases characterized by increased resorption (BOYCE & XING, 
2008). RANK-RANKL signaling not only activates a variety of downstream 
signaling pathways required for osteoclast development, but also fine-tunes bone 
homeostasis both in normal physiology and disease via crosstalk with other 
signaling pathways. Interestingly all factors that inhibit or enhance bone 
resorption by osteoclasts also positively or negatively influence RANKL and OPG 
mRNA levels as well as protein levels (LEIBBRANDT & PENNINGER, 2008). 
3.1.2. RANKL  
RANKL is a member of the tumor necrosis factor (TNF) family, respectively its 
receptor RANK and its decoy receptor OPG belong to the TNF receptor family 
(KEARNS et al., 2008). RANKL exists as a homotrimeric protein and is typically 
membrane-bound on osteoblasts and activated T cells. There is also a soluble 
form which is secreted either through proteolytic cleavage of the membrane form 
or through alternative splicing. Most factors known to stimulate osteoclast 
formation and activity induce RANKL expression by osteoblastic stromal cells 
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(BOYCE & XING, 2008). Membrane bound RANKL ensures cell-cell contact 
allowing only microenvironmental function, whereas soluble RANKL can diffuse 
to the target cells leading to a systemic function. When more RANKL is released 
by osteoblasts, bone resorption will be increased through osteoclast 
differentiation, activation and survival (WRIGHT et al., 2009).  
3.1.3. RANK 
RANK is a type I transmembrane glycoprotein, expressed on the surface of 
osteoclast precursors, mature osteoclasts, dendritic cells, mammary gland 
epithelial cells and cancer cells. When RANKL binds to its receptor RANK a 
signaling cascade is initiated and in this activation process the following factors 
are involved: cytoplasmic adaptor protein TRAFs, followed by the downstream 
pathways including NF-kappaB, c-jun N-terminal kinase (JNK) or Src (proto-
oncogenic tyrosine kinases) pathways. This leads to the expression of various 
genes, which facilitate the differentiation of monocytes into osteoclasts and also 
the activation of mature osteoclasts as well as their enhanced survival (WRIGHT 
et al., 2009).  
3.1.4. OPG 
Osteoprotegerin was named so for its protective effects in the bone. OPG is a 
soluble glycoprotein secreted by osteoblasts and other mesenchymally derived 
cells. It is a factor without any transmembrane or cytoplasmic domain. OPG 
functions as a decoy receptor through binding with high affinity to RANKL, 
therefore the true receptor RANK will not be activated. Thus OPG inhibits 
osteoclast differentiation, activation and survival and therefore preserves bone 
substance (WRIGHT et al., 2009).  
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Figure 1: RANKL/RANK/OPG axis. RANKL expression is induced in 
osteoblasts and bone marrow stromal cells, and subsequently binds to its 
specific membrane-bound receptor RANK, that promotes osteoclast 
differentiation, activation and survival. OPG binds and neutralizes RANKL 
(BOYLE et al., 2003) 
 
a) Pro-resorptive and calcitropic status 
 
b) Anabolic and anti-osteoclastic status 
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3.2. RANKL/RANK/OPG axis in the state of disease 
Estrogen deficiency in osteoporosis leads to an up regulation of RANKL, which 
increases bone turnover, whereas estrogen itself stimulates OPG production in 
osteoblasts and thus displays anti-resorptive effects (SIPOS et al., 2009). 
Duplications in the signal peptide of RANK have been linked to four families 
with familial expansile osteolysis or Paget disease of the bone, a rare autosomal 
dominant bone dysplasia characterized by focal areas of increased bone 
remodeling. Several mutations affecting the ligand binding domain of OPG have 
been found in patients suffering from juvenile Paget disease, an autosomal 
recessive osteopathy described by elevated bone remodeling, osteopenia, fractures 
and progressive skeletal deformity (LEIBBRANDT & PENNINGER, 2008). 
Serum RANKL levels are not clearly associated with bone mineral density, but 
with nontraumatic fractures. However, in one of the studies over half of the 
women (54.9%) had undetectable RANKL concentrations, and in another study 
40% of samples were under the limit of detection (KEARNS et al., 2008). Levels 
of RANKL in the bone microenvironment may be more relevant. In a study, the 
cell surface concentration of RANKL was examined in connection with 
osteoporosis prevalence. Their findings suggest that up-regulation of RANKL on 
bone marrow cells is correlated with increased bone resorption induced by 
estrogen deficiency (KEARNS et al., 2008). During 28 days of continuous 
RANKL infusion, rats developed overall skeletal complications comparable to 
those in high bone turnover conditions, such as postmenopausal osteoporosis 
(YUAN et al., 2008). In the mouse three times injection of soluble RANKL 
leaded to a dose-dependent decrease of bone mineral density. It was assumed that 
bone loss easily could be controlled by varying the amount of injected sRANKL 
(TOMIMORI et al., 2009). The knowledge about the functionality of RANKL 
pathways leaded to new approaches for modern therapies, for example anti-
RANKL monoclonal antibodies like Denusomab (Prolia®), which after the 
successful completion of phase III clinical trials are now released for the broadly 
treatment of osteoporosis (DOGGRELL, 2009; WRIGHT et al., 2009; 
UNIVERSIMED, 2010). Inhibition of RANKL function might be the most 
rational therapy to improve many osteopenic conditions and prevent bone 
destruction and cartilage damage in osteoporosis and arthritis (LEIBBRANDT & 
PENNINGER, 2008).  
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3.3. sRANKL transgenic mice 
The group of Mizuno et al. generated two types of transgenic mice overexpressing 
soluble RANKL via DNA microinjection. One transgenic line CAG-promoter-
sRANKL overexpressed sRANKL ubiquitously from an early developmental 
stage on, the other transgenic mouse line SG2-sRANKL overexpressed sRANKL 
only in the liver after birth. Unexpectedly, in the CAG-sRANKL line ubiquitous 
overexpression in the fetal stage resulted in a lethal phenotype. Also in the other 
line SG2-sRANKL some of the fetuses died at birth, but most of them grew up to 
adults and were fertile. As conclusion it is impossible to obtain living sRANKL 
transgenic progeny when the overexpression takes place uncontrolled during fetal 
development stage. In SG2-sRANKL mice at the age of 7-8 months the bone 
mineral density of femurs was significantly lower than in control mice. 
Additionally, the histological analyses revealed that trabecular bone mass was 
rapidly reduced with aging. Bone strength and stiffness were also markedly 
decreased. Bone resorption was increased by enhanced osteoclastogenesis and 
osteoclast activation (MIZUNO et al., 2002). These sRANKL overexpressing 
mice show a similar osteoporotic phenotype as OPG-deficient mice. The main 
difference between these both are that OPG-deficient mice have a low body 
weight and deformed skeletons, even before they are weaned. In contrast 
sRANKL transgenic mice have a normal body weight through their whole lifetime 
and there is no bone deformation in infants. Additionally, sRANKL transgenic 
mice exhibit a milder osteoporotic phenotype and lower serum ALP levels than 
OPG-deficient mice (BUCAY et al., 1998; MIZUNO et al., 1998; MIZUNO et al., 
2002). 
4. Gene regulation by a tetracycline inducible system 
4.1. Inducible gene regulation 
One powerful approach available to scientists is transgenic overexpression of 
genes of interest in animal models to study the role of these genes in vivo (SUN et 
al., 2007). But soon limitations of promoter-controlled transgene expression 
became obvious, because the constitutive system has no control over the timing of 
the expression. Constitutively active promoters mostly start transcription early in 
embryonic stage. If the transgene product is toxic to the embryo or fetus, this will 
result in failure to generate live progeny carrying the transgene. To address these 
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limitations different inducible transgenic modeling systems were established 
(ZHU et al., 2002). The most prominent and widely-accepted inducible systems so 
far are based on the tetracycline-controlled transcriptional regulator developed by 
Gossen and co-workers (GOSSEN & BUJARD, 1992; GOSSEN et al., 1995; 
STIEGER et al., 2009). To generate credible transgenic animal models to 
precisely mimic human disease states, it is critical to tightly regulate gene 
expression in the animals in a conditional manner. The ability to turn gene 
expression ―on‖ or ―off‖ in restricted cells or tissues at specific time points opens 
up a new level of research (SUN et al., 2007). Tetracycline (Tet) regulatable 
systems are based on the E. coli tetracycline resistance operon, which consists of 
the Tet repressor (TetR) protein and the Tet operator (TetO) DNA sequence 
(WISSMANN et al., 1986). In the absence of tetracycline or its derivate 
doxycycline (Dox), the TetR protein gets attached to the TetO DNA sequence, 
while in the presence of the drug, TetR changes its conformation to detaching 
from the DNA (ORTH et al., 1998). There are two basic variants of the 
tetracycline-inducible system: if transgene expression is allowed only in the 
absence of doxycycline, the system is called Tet-Off, whereas if transgene 
expression is allowed only in the presence of Dox, the system is called Tet-On 
(SUN et al., 2007; STIEGER et al., 2009).  
4.2. Tet-Off (tTA) 
The Tet-Off (tTA) system is suitable to maintain a long-time gene expression. To 
turn the system off, continuous administration of doxycycline (Dox) would be 
required (STIEGER et al., 2009). Especially when development-independent or 
adult-onset processes are under investigation and the target gene needs to be kept 
silent at embryonic and neonatal stage, long-term administration of Dox is 
required and may become a burden with undesired side effects (ZHU et al., 2002). 
In the absence of the regulating agent doxycycline, tTA binds the responsive 
elements tetracycline-resistance operon of E. coli transposon (TetO) and activates 
the minimum promoter from human cytomegalovirus (Pcmv) leading to 
transcription and expression of the downstream target gene. In the presence of 
Dox, tTA dissociates from TetO and terminates transcription of the target gene 
(ZHU et al., 2002). The activation of transgene expression may take several days, 
depending on the clearance kinetics of Dox from the system (ZHU et al., 2002; 
STIEGER et al., 2009).  
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These shortcomings limited the use of the Tet-Off system and leaded to the 
development of a new tetracycline depend system.  
Figure 2: Tetracycline-controlled transcriptional activator (tTA) system: 
“Tet-Off” (ZHU et al., 2002) 
 
4.3. Tet-On (rtTA) 
The Tet-On (rtTA) system was created by mutations in the TetR domain of the 
transactivator tTA (Tet-Off), leading to a reverse behavior of the protein in 
interaction with the tetracycline response element (TRE) in the response to the 
presence or absence of Dox (GOSSEN et al., 1995). The main diversification in 
the Tet-On system is that only the presence of the inducer drug allows expression 
of a transgene. In the absence of Dox, rtTA does not bind to TetO and as a 
consequence no transcription of the target gene will take place. In the presence of 
Dox, rtTA binds to TetO and initiates the transcription of the target gene (ZHU et 
al., 2002). The activation of transgene expression was found to be more rapid 
compared to the Tet-Off system (GOSSEN et al., 1995; KISTNER et al., 1996; 
STIEGER et al., 2009). The rtTA system (Tet-On) has been used successfully in 
numerous transgenic mouse models with variety of transgenes targeted at various 
tissues and organs (KISTNER et al., 1996; ZHU et al., 2002; BACKMAN et al., 
2009; RAO & MONKS, 2009; SONG et al., 2009).  
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Figure 3: Reverse tetracycline-controlled transcriptional activator (rtTA) 
system: “Tet-On” (ZHU et al., 2002) 
 
4.4. Doxycycline 
The inducer drug doxycycline, an analogue of tetracycline, is a well-documented 
antibiotic drug that has been used in the clinics for more than 30 years. Therefore 
it is considered as a save agent that can be used without major concern. The 
bioavailability of Dox after oral administration compared to intravenous 
administration is almost 100% and the serum half-life has been calculated to 14–
22 h. The tissue penetration is excellent and includes the brain. Concentrations are 
the highest in liver, kidney and digestive tract, as it is eliminated primarily via 
urine and faeces (AGWUH & MACGOWAN, 2006; STIEGER et al., 2009). In 
Tet-inducible system transgenic mouse models doxycycline is administrated 
dissolved in the drinking water at ad libitum supply (KISTNER et al., 1996; RAO 
& MONKS, 2009). The Tet-based systems are steadily evolving towards an ideal 
inducible transgenic system, especially because they are coupled with a simple, 
well-understood, inexpensive, and easy-to-use inducing agent, doxycycline (ZHU 
et al., 2002). 
5. Techniques of transgenesis in pigs 
5.1. DNA Microinjection 
Pronuclear DNA microinjection is seen as the injection of a gene construct 
directly into the pronucleus of zygotes. To hinder a mosaic integration and 
expression of the foreign gene, the DNA microinjection must take place at the one 
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cell stage (HOUDEBINE, 2005). This method was first established in the mouse 
(GORDON & RUDDLE, 1981) before being applied to various other mammalian 
species including the pig (BREM et al., 1985; HAMMER et al., 1985). Generally 
the efficiency of DNA microinjection is low. In the mouse the efficiency is 1-3% 
transgenic animals per microinjected embryos. In the pig the success of obtaining 
transgenic progeny is even lower, the same as in other animals like rabbits, rats 
and ruminants (HOUDEBINE, 2005). This inefficiency required microinjection 
and transfer of thousands of embryos to produce few transgenic offspring. In the 
end it is very costly to produce one single transgenic animal by DNA 
microinjection (ROBL et al., 2007). If integration of exogenous DNA occurs after 
embryonic cleavage begins, mosaic offspring can be obtained. For the species 
mouse the random integration of microinjected DNA has shown to bear a risk of 
insertional mutagenesis (RIJKERS et al., 1994). However, for pig, pathological 
side effects which could putatively be associated with insertional mutagenesis 
after DNA microinjection have not been reported so far (DEPPENMEIER et al., 
2006). Nevertheless, expression levels of the transgene can differ due to position 
effects and variable numbers of integrated copies. An approach to reduce cost and 
labor of pronuclear microinjection would be the use of porcine embryos produced 
by in vitro fertilization (NAGASHIMA et al., 2003). Ovaries collected from 
slaughtered gilts are a source for oocytes, which undergo in vitro maturation 
(IVM) and in vitro fertilization (IVF). Resulting embryos would subsequently 
undergo DNA microinjection before being transferred to recipient sows. In vitro 
production systems yielding viable pig embryos and healthy piglets have been 
established (KIKUCHI et al., 2006), but still remain to be optimized 
(ALMINANA et al., 2008; GIL et al., 2008; KIKUCHI et al., 2008). Despite the 
overall low efficiency, most of the transgenic pig lines existing so far have been 
established by pronuclear microinjection technique. However other techniques of 
transgenesis have gained importance due to their higher efficiency and the 
potential to introduce targeted modification in the pig genome. 
5.2. Sperm mediated gene transfer 
Sperm cells are capable of binding and internalizing DNA molecules. This ability 
is used in sperm mediated gene transfer (SMGT) to transport exogenous DNA 
during fertilization into the embryo (LAVITRANO et al., 2006). SMGT is 
achieved by collection of sperm, co-incubation of sperm with exogenous DNA 
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and artificial insemination of gilts with DNA-loaded sperm. In 1989 the first 
transgenic mouse was produced by SMGT (LAVITRANO et al., 1989) and the 
first transgenic pig followed in 1997 (LAVITRANO et al., 1997). The big 
advantages of this method are its simplicity and the low costs. Unfortunately, the 
mechanism of DNA uptake by sperm during the co-incubation period is poorly 
characterized. A problem is the high variability of this method, which is showing 
in difficulties in reproducibility and low efficiency (ROBL et al., 2007). The crux 
of the matter seems to be the selection of the right sperm donor animals 
(LAVITRANO et al., 2003). It has been hypothesized that sperm from different 
boars differ in their ability to bind exogenous DNA which would explain the high 
variability of the SMGT method. In vitro incubation of radioactively labeled DNA 
with sperm showed that the DNA uptake of the sperm was highly correlated with 
sperm motility at the time of collection (WU et al., 2008b). Anyway it was shown 
that it is possible to produce piglets with a stable expression of the desired 
transgene (hDAF) and this founder animals passed the hDAF gene to their 
progeny (LAVITRANO et al., 2002; LAVITRANO et al., 2006). Other 
laboratories were also able to reach considerable transgene integration rates (WU 
et al., 2008b), but these piglets just showed transient transgene expression. New 
approaches to enhance efficiency and lower variability are linker base SGMT and 
intracytoplasmatic sperm injection (ICSI) mediated gene transfer. In Linker based 
SMGT, a monoclonal antibody is used which binds specifically to sperm cell 
surface by recognizing a specific antigen and DNA by its C-terminal end 
(HOUDEBINE, 2005). This is improving the uptake of exogenous DNA through 
receptor-mediated endocytosis. The transgenic sperm was transferred to sows 
through surgical oviduct insemination. The method has been reported to yield 
transgenic offspring (CHANG et al., 2002). As in SMGT, a central step of ICSI 
mediated gene transfer is the incubation of male germ cells with exogenous DNA. 
If the sperm membrane is disrupted, exogenous DNA could be more efficiently 
transferred into pig oocyte. First ICSI experiments using sperm that had been 
preincubated and then co-injected with exogenous DNA yielded in transgenic 
blastocysts which showed GFP (green fluorescent protein) expression 
(NAGASHIMA et al., 2003). With a new protocol of sperm pretreatment to 
disrupt the sperm membrane, it was also possible to obtain viable transgenic 
piglets (KUROME et al., 2007). Other groups succeeded in production of 
transgenic embryos via ICSI mediated gene transfer as well (WU et al., 2008a). 
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Clearly, more work is needed before SMGT is widely applied (ROBL et al., 
2007). 
5.3. Lentiviral gene transfer 
The principle of lentiviral gene transfer is based on infection of porcine zygotes 
with retroviral vectors carrying transgenes. Lentiviruses belong to the family of 
retroviruses. Irrespective of cell cycle they can reach the host genome, because 
they can pass the nuclear membrane. So they are capable of infecting quiescent 
and embryonic cells (HOUDEBINE, 2005; ROBL et al., 2007), which reduces the 
formation of mosaics. Based on these advantages, lentiviral vectors are actually 
considered to be the most efficient method of viral transgenesis (ROBL et al., 
2007). The generation of transgenic mice and rats using lentiviral gene transfer 
was first reported in 2002 (LOIS et al., 2002; PFEIFER et al., 2002). In the pig, 
lentiviral vectors based on the human immunodeficiency virus-1 (HIV-1) and on 
the equine infectious anemia virus (EIAV) were used for gene transfer. The 
recombinant lentiviruses were injected under the zona pellucida of zygotes, which 
were transferred to synchronized recipients later on.  The overall efficiency of 
generating transgenic pigs by lentiviral gene transfer ranged at 13% (transgenic 
offspring per infected and transferred embryo) (HOFMANN et al., 2003; 
WHITELAW et al., 2004). A high proportion of transgenic G0 animals (94%) 
showed transgene expression, also over a long time (6 months) (PFEIFER et al., 
2004). However, lentiviral vectors are limited to a DNA uptake only between 8-10 
kb of foreign DNA, and they lead to varying gene expression in the transgenic 
pigs (HOUDEBINE, 2005; ROBL et al., 2007) and their progenies. The Hofmann 
group reported about low expression levels and hypermethylation in one third of 
G1 offspring, due to multiple integration sites in the founder animals, which 
segregated in the following generations (HOFMANN et al., 2006).  
5.4.  Somatic cell nuclear transfer (SCNT)  
The generation of transgenic pigs by cloning is a multiple-step technology, 
including: transfection or transduction and selection of donor cells in cell culture; 
in vivo or in vitro maturation of oocytes; enucleation of the recipient oocytes; 
donor cell nucleus transfer; fusion of donor cell with recipient oocytes cytoplasm; 
artificial activation; in vitro culture of the reconstructed embryos and embryo 
transfer into synchronized recipient sows. The proof of concept of cloning was 
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confirmed in the sheep (SCHNIEKE et al., 1997; WILMUT et al., 1997), before 
being applied to the pig (BETTHAUSER et al., 2000; ONISHI et al., 2000; 
POLEJAEVA et al., 2000). Attractive characteristics of SCNT are the avoidance 
of mosaic phenotypes and the possibility of pre-selection of donor cells with 
regard to transgene expression or gender (LEE et al., 2005). SCNT exclusively 
enables gene targeting in pigs (PHELPS et al., 2003; RAMSOONDAR et al., 
2003; TAKAHAGI et al., 2005) and assembling multiple genetic modification in 
a single pig line (ROBL et al., 2007). Sequential modifications cannot be done in 
a single step of cell culture, when primary cells with finite life spans are used. It 
requires serial cloning, where in each cloning step another genetic modification 
can take place (ROBL et al., 2007). Serial cloning has been reported up to three 
generations, with no negative impact on cloning efficiency and health of cloned 
offspring (CHO et al., 2007; KUROME et al., 2008). However, the efficiency of 
cloning is varying within relatively low values between 0.5% - 5.1% offspring per 
transferred SCNT embryos (DAI et al., 2002; KUROME et al., 2008). 
Considering the poor in vitro developmental competence of SCNT embryos, 
scientists prefer to transfer a high number of embryos (50-150) into each recipient 
after a short period of in vitro culture (1-8 cell stage) (VAJTA et al., 2007). 
Groups which perform SCNT on a regular and consistent basis tend to have better 
results, because routines are followed consistently and speedy completion of the 
NT-process results in minimal exposure of oocytes to detrimental conditions 
(KEEFER, 2008). Low efficiency in SCNT is based on the cumulative loss of 
cloned embryos and fetuses at every stage of development (KISHIGAMI et al., 
2008). Increased mortality rates and health problems such as postnatal respiratory 
distress, contracture of the flexor tendon, enlarged tongue, cerebromeningitis, 
hemodynamic disorder and decreased birth weight have been reported in 
transgenic cloned piglets (LEE et al., 2003; PRATHER et al., 2004; PARK et al., 
2005). Compared with cloned cattle and sheep, perinatal death and birth defects 
occur less frequently (CIBELLI et al., 2002; RUDENKO & MATHESON, 2007; 
KEEFER, 2008). As these abnormal phenotypes are usually not transmitted to 
offspring of the clones, they are apparently a result of epigenetic modification 
(PARK et al., 2002; KISHIGAMI et al., 2008). These dangers can be sidestepped 
by breeding the clones, as soon as they reach puberty (PEARSON, 2003; MIR et 
al., 2005). Despite of the low overall efficiency, SCNT is regarded as the most 
reliable approach to produce piglets with targeted genetic modifications (VAJTA 
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et al., 2007). Future research should focus on improving the health and production 
efficiency of somatic cell porcine clones (MATSUNARI & NAGASHIMA, 
2009). 
6. Examples of genetically modified pigs 
6.1. Swine in biomedical research 
Transgenic pigs are generated for biomedical research purposes, i.e. as animal 
model in medical research, as donor animal for xenotransplantation, as bioreactors 
for gene farming and as highly efficient productive livestock in agriculture. 
Among various possibilities, the established somatic cell nuclear transfer system 
with genetically engineered donor cells is an efficient and reliable approach to 
produce transgenic pigs (VAJTA et al., 2007). Various human disease models and 
donor pigs for xenotransplantation have been produced via SCNT. 
6.2. Transgenic human disease models 
6.2.1. Human heart disease model 
Endothelial cell nitric oxide synthase (eNOS) over-expressing piglets were 
generated by nuclear transfer to study the role of nitric oxide metabolism in 
cardiac and skeletal muscle. The final goal was to generate large animal model for 
human heart disease (HAO et al., 2006). Nitric oxide (NO) is a messenger 
molecule, which modulates vascular function, structure and homeostasis. The 
enzyme endothelial cell nitric oxide synthase (eNOS) releases NO into the blood 
stream, where it plays an important role in the metabolism of cardiac and skeletal 
muscle. The created pigs carried the Tie2-eNOS transgene and also showed 
expression of the Tie2-eNOS in the endothelial cells of placental vasculature 
simultaneously to the endogenous eNOS (HAO et al., 2006).  
6.2.2. Cystic fibrosis model 
Cystic fibrosis (CF) is the most common lethal genetic disease in the Caucasian 
population (CARVALHO-OLIVEIRA et al., 2007), caused by mutations in the 
gene encoding the CF transmembrane conductance regulator (CFTR) 
(MATSUNARI & NAGASHIMA, 2009). CFTR knock-out mice failed to develop 
pulmonary and pancreatic symptoms, the leading causes of morbidity and 
mortality in CF patients (CARVALHO-OLIVEIRA et al., 2007; GUILBAULT et 
II. Literature     25 
al., 2007). Due to many anatomical and physiological similarities, pigs were 
considered as a more suitable animal model. CFTR knockout pigs developed 
meconium ileus, exocrine pancreatic destruction, and focal biliary cirrhosis, 
replicating abnormalities seen in newborn patients with CF (ROGERS et al., 
2008). Additional the CF pigs showed few months after birth already typical lung 
symptoms like airway inflammation, mucus accumulation and infection (STOLTZ 
et al., 2010). 
6.2.3. Alzheimer´s disease model 
Disease-causing mutations for Alzheimer’s disease (AD) were identified in the 
amyloid precursor protein gene (APP) and the presenilin 1 and presenilin 2 genes 
(PSEN1 and PSEN2). These mutations are associated with accumulation of the 
Aß peptide in the brain. Transgenic pigs were produced expressing the neuronal 
variant of the human amyloid precursor protein based on the Swedish APP 
mutation (KRAGH et al., 2009). APP695sw transgene expression, including 
protein, was observed in brain tissue and not in heart or liver tissues. Mutant 
protein accumulation will approximately take 1-2 years, and it’s expected that 
after this time the transgenic pigs show the desired phenotype.  
6.2.4. Diabetes mellitus type 3 model  
Diabetes mellitus, one of the most serious chronic diseases in modern society 
(RATHMANN & GIANI, 2004), is characterized by high blood glucose levels 
and complications such as diabetic retinopathy, diabetic nephropathy and diabetic 
neuropathy. A model for maturity-onset diabetes of the young type 3 (MODY3) 
was developed by integrating a dominant-negative mutant hepatocyte nuclear 
factor 1alpha into pigs (UMEYAMA et al., 2009). These pigs manifested the 
pathophysiology of diabetes, such as high fasting blood glucose levels 
(>200mg/dl), abnormal formation of Langerhans islets and poor insulin secretion.  
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Table 2: Human disease models produced by SCNT  
Objective of 
investigation 
Gene Reference Technique 
Human Nitric 
oxide metabolism 





(HAO et al., 
2006) 
SCNT 
Cystic fibrosis Disruption of the 
CFTR gene 






















Because of the world-wide shortage of human organs, researchers began with 
their studies on xenotransplantation (COZZI et al., 2009). Several genetically 
modified strains of pigs, representing different strategies against human rejection 
mechanisms, have already been generated by pronuclear DNA injection, sperm 
mediated gene transfer or SCNT (SACHS & GALLI, 2009). The rejection of a 
foreign organ can be classified in different stages: hyperacute rejection (HAR), 
acute humoral xenograft rejection (AHXR), immune cell-mediated rejection, and 
chronic rejection (KLYMIUK et al., 2010). Hyperacute rejection develops within 
24 hours. It is mediated by the binding of preexisting xenoreactive antibodies to 
endothelial cells and activation of the complement system, which results in 
endothelial swelling and microvascular thrombosis (SCHUURMAN et al., 2003; 
SPRANGERS et al., 2008). The xenoantibodies are predominantly directed 
against α-1,3-Galactosyl (αGal) carbohydrate residues. These are expressed on 
endothelial cells of non-primate mammals, but are absent in humans, apes, and 
old world monkeys as these species lack the αGal-transferase gene to synthesize 
αGal. Because of cross-reactivity to surface antigens of the intestinal flora, natural 
anti-αGal antibodies are produced as soon as the gastrointestinal tract is 
encountered by microorganisms shortly after birth (SPRANGERS et al., 2008). In 
the year 2002 a breakthrough in pig genetic engineering was the birth of the first 
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homozygous Knockout of α-1,3-galactosyltransferase (αGalT) piglets (DAI et al., 
2002; LAI et al., 2002; PHELPS et al., 2003; RAMSOONDAR et al., 2003; 
WATT et al., 2006; FUJIMURA et al., 2008), from that day on it was proven that 
gene targeting in the pig is possible (KLYMIUK et al., 2010). Development of 
αGal deficient pigs has reduced or eliminated the significance of αGal antigen in 
xenograft rejection. When αGal deficient pig organs are used for Pig-to-Primate 
Cardiac Xenotransplantation, xenograft rejection remains associated with 
antibody deposition, variable complement activation and microvascular 
thrombosis. Nevertheless organs from αGal knock out pigs are widely considered 
to be central for clinical xenotransplantation of solid organs (BYRNE et al., 
2008).  
7. Embryo transfer (ET) in the pig 
7.1. Factors influencing ET success 
The first birth of piglets after embryo transfer (ET) was reported in the year 1950 
in Poltava, Ukraine (KVASNITSKI, 1950). Since then progress in reproductive 
biotechnologies has led to an increased use of embryo transfer in both swine 
research and swine production. The number of embryo transfers performed in pigs 
is low compared with that in cattle, despite the fact that bovine embryo transfer 
technology was developed at the same time (YOUNGS, 2001; VAJTA et al., 
2007). This is due to the fact that rapid genetic improvement in pig easily can be 
achieved by selection programs without the use of embryo transfer. Another 
impediment to the widespread use of ET in the swine industry is that 
cryopreserving pig embryos is still no routine technology (HAZELEGER & 
KEMP, 2001; YOUNGS, 2001). There are various factors which might influence 
ET successes. One factor is synchronization of estrus cycle of recipient sow and 
development stage of transferred embryos. It is common to use hormones, first 
equine chorionic gonadotropin (eCG) followed by human chorionic gonadotropin 
(hCG), to induce estrus in gilts close to puberty. The eCG stimulates follicular 
development due to its FSH-like activity, and hCG causes ovulation because of its 
LH-like activity (YOUNGS, 2001). Accurate synchronization of the recipient gilt 
is crucial to the success of ET. A delay of 48 hours between donor and recipient 
estrus resulted in the degeneration of all embryos (GEISERT et al., 1991).  
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7.2. Pregnancy rates 
First-estrus gilts are contraindicated for donating embryos, but they are quite 
acceptable as recipients. No difference in pregnancy rate (67.5% vs. 60%) or 
embryonic survival (69% vs. 75%) was reported in first-estrus versus third-estrus 
recipient gilts, respectively (ARCHIBONG et al., 1992). No evidence of uterine 
crowding adversely affecting litter size at Day 25 of gestation in females having 7 
or fewer embryos present per uterine horn has been observed, suggesting that a 
minimum of 14 embryos should be transferred to each recipient (DZIUK, 1968). 
Pregnancy rates of 71% and 100% and embryo survival rates of 57% and 68% in 
gilts receiving 12 or 24 embryos, respectively, were reported (POPE et al., 1972). 
It was also reported that at least four viable embryos were necessary in pigs to 
maintain pregnancy in the early phases of embryo maternal communication 
(POLGE et al., 1966). Average pregnancy rates of 60% and embryonic survival 
rates (in pregnant recipients) of 60% are standard. So from all transferred embryos 
35-40% survive and will result in living piglets. In all these experiments in vivo 
derived embryos were used and the success rate surely is lower, when dealing 
with manipulated embryos (YOUNGS, 2001).  
7.3. Endoscopic embryo transfer 
The surgical procedures of ET have been refined to a minimally invasive 
procedure, using endoscopy for transfer of embryos. Although they can be defined 
as surgical techniques, their advantage is that only a few small incisions are 
needed for insertion of instruments onto the abdominal cavity. Additionally 
endoscopy allows pre-examining the genital tract for reproductive abnormalities 
and successful ovulation without exposure and exteriorization of viscera during 
surgery (BESENFELDER et al., 1997; HAZELEGER & KEMP, 2001). 
Pregnancy rates up to 90 % were reported following routine application of 
endoscopic embryo transfer. The main disadvantage of this technique is that 
skilled personnel, anesthesia and surgical facilities are required (HAZELEGER & 
KEMP, 2001).  
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III. MATERIALS AND METHODS 
1. Equipment and expendable items 
1.1. In vitro works 
Petri dishes:    35x10 mm, Becton Dickinson Labware 
     50x9 mm, Becton Dickinson Labware 
     60x15 mm, Nunc® Brand Products  
Glassware:    Schott, Brand, Wertheim 
Pipettes:       Eppendorf, Hamburg 
Pipette filter tips:    Eppendorf, Hamburg 
Neubauer counting chamber:  Brand, Wertheim 
Centrifuge tubes:     15 ml, Greiner 
     50 ml, Falcon®, Becton Dickinson Labware  
Glass cover slips:    Marienfeld, Lauda-Koenigshofen 
Reaction tubes:     0.5 ml / 1.5 ml / 2 ml, Eppendorf 
Sterile benches:   Lamin Air®, HB 2472, Heraeus 
KR-130 BW, Kojair 
Sterile filters:    Millipore Express®, 0.22μm, Millex® GP 
Centrifuges:     Biofuge pico, Heraeus 
     Rotanta 96, Hettich Zentrifugen 
Incubator:    Type B 5060, Heraeus 
     Model 500M, MMM Group 
Microscopes:    Leitz Periplan, Leica 
     Stermi SV6, Zeiss 
     SMZ-10A, Nikon 
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Micromanipulator:   Eclipse TE 2000-U, Nikon 
     Eclipse TE 300, Nikon 
Warming plates:    HT 200, Minitube 
Electro activation:   Multiporator, Eppendorf 
Electro cell fusion:   Model LF 101, Nepa Gene  
Cell transfection:   Nucleofector® II, Amaxa biosystems 
1.2. Embryo transfer 
Endoscopic instruments:  Karl Storz Endoskope 
Ultrasonic device:    Echo camera, SSD-500, Aloka 
2. Used media and stock solutions 
2.1. Stock solutions  
PBS (Phosphate-buffered saline) 
8.00 g  NaCl     (Sigma) 
0.20 g  KCl     (Sigma) 
1.15 g  Na2HPO4 x 2 H2O   (Fluka, Neu-Ulm) 
0.20 g  KH2PO4    (Merck, Darmstadt) 
0.10 g  CaCl2     (Sigma) 
0.10 g  MgCl2 x 6 H2O   (Sigma) 
1.0 l  Milli-Q water 
sterile filtered, stored at room temperature 
PBS− (Phosphate-buffered saline without calcium and magnesium) 
8.00 g NaCl 
0.20 g KCl 
2.14 g Na2HPO4 x 7 H2O   (Merck) 
0.20 g KH2PO4 
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1.0 l Milli-Q water 
sterile filtered, stored at room temperature 
PBS P/S (Phosphate-buffered saline with 2 % Penicillin/Streptomycin) 
98 ml  PBS 
2 ml  Pen/Strep stock solution 
freshly prepared before use 
Pen/Strep stock solution 
0.65 g Penicillin    (Seromed, Berlin) 
1.33 g  Streptomycin    (Seromed) 
100 ml  Milli-Q water 
(contains 100 U/ml penicillin and 100 µg/ml active streptomycin) 
sterile filtered, stored at -20°C 
2.2. Cell culture  
Culture media for porcine fibroblasts and kidney cells: 
DMEM (high glucose, without sodium pyruvate)   (GIBCO) 
1% non-essential amino acids    (GIBCO) 
1% sodium pyruvate      (GIBCO) 
0.1 mM Mercaptoethanol (7 µl/10 ml PBS 1%)  (Sigma) 
1% L-Glutamin 200 mM + 1% Pen/Strep    (PAA)  
10-15% FKS        (GIBCO) 
Serum Starvation media 
DMEM (high glucose, without sodium pyruvate)  (GIBCO) 
1% non-essential amino acids    (GIBCO) 
1% sodium pyruvate      (GIBCO) 
1% L-Glutamin 200 mM + 1% Pen/Strep     (PAA) 
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0.5 % FKS        (GIBCO) 
Trypsin/EDTA-solution for cell culture 
Trypsin 0.25%      (Difco) 
EDTA 0.02%     (Sigma) 
PBS- (without calcium and magnesium) 
sterile filtered, stored at -20°C 
G418 selection Media  
Porcine fibroblast culture medium (see above) 
G418 (Geneticin)     (GIBCO) 
Porcine kidney cells: 1.2 mg/ml  
Porcine fetal fibroblast cells: 0.6 mg/ml 
2.3. Nuclear transfer  
NCSU-23 Stock A 
NaCl     6.355 g  (Sigma) 
KCl   0.356 g  (Sigma) 
MgSO4 x 7 H2O 0.293 g   (Sigma) 
KH2PO4  0.162 g   (Sigma) 
Milli-Q water  restocked up to 100 ml 
sterile filtered, stored at 4°C 
NCSU-23 Stock B 
CaCl2 x 2 H2O 0.5 g   (Sigma) 
Milli-Q water  restocked up to 20 ml 
sterile filtered, stored at 4°C 
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Ready to use NSCU-23 
NaHCO3  0.421 g  (Sigma) 
Glucose  0.2 g   (Sigma) 
PenicillinG  0.013 g  (Sigma) 
Streptomycin  0.010 g  (Sigma) 
Taurine  0.175 g  (Sigma) 
Stock A  20 ml 
Stock B  2 ml 
Milli-Q water  restocked up to 200 ml 
sterile filtered, stored at 4°C 
Hepes-TaLP-PVP Stock A 
NaCl   6.66 g   (Sigma) 
KCl   0.24 g   (Sigma) 
MgCl2 x 6 H2O 0.1 g   (Sigma) 
NaH2PO4  0.042 g  (Sigma) 
Na Lactate (60%) 1.85 ml  (Sigma) 
Phenol red  2 ml   (Sigma) 
Milli-Q water  restocked up to 100 ml 
sterile filtered, stored at 4°C 
Hepes-TaLP-PVP Stock B 
CaCl2 x 2 H2O  0.58 g   (Sigma) 
Milli-Q water  restocked up to 20 ml 
sterile filtered, stored at 4°C 
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Hepes-TaLP-PVP Stock C 
Hepes   2.4 g   (Sigma) 
Milli-Q water  restocked up to 100 ml 
sterile filtered, stored at 4°C 
Ready to use Hepes-TaLP-PVP 
Glucose  0.45 g   (Sigma) 
Sorbitol  4 g   (Sigma) 
PVP   1.5 g   (Sigma) 
Streptomycin  0.025 g  (Sigma) 
PenicillinG  0.033 g  (Sigma) 
NaHCO3  0.085 g  (Sigma) 
Stock A  50 ml 
Stock B  5 ml 
Stock C  50 ml 
Milli-Q water  restocked up to 500 ml 
sterile filtered, stored at 4°C 
Porcine zygote medium 
PZM-5  Institute for the functional Peptide, Yamagata, Japan  
3. Establishment of transgenic cell lines 
3.1. Cells  
For transfection, porcine fetal fibroblasts (PFF) were obtained from 28 and 35 
days old male wild type pig fetuses and tested in vitro for their SCNT 
development capacity. For recloning and additional transfection the following cell 
types were used: PFF, porcine ear fibroblasts (PEF), porcine kidney cells (PKC). 
As donation of other laboratories we received several different transgenic cell 
lines to perform somatic cell nuclear transfer and to produce transgenic offspring. 
These donated cell lines originated from mesenchymal stem cells (MSC) or PFF.   
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3.2. Transfection of cells  
To establish a stable cell line expressing the desired construct plus antibiotic 
resistance, wild type fetal fibroblasts were electroporated by the Nucleofector® 
system. The foreign DNA was introduced into the cell by an electro current. Cells 
were harvested after passage three and counted in a Neubauer counting chamber. 
5 μl DNA-solution (3.3 μg) containing the chosen gene construct and 100μl 
human dermal fibroblast Nucleofector® solution were mixed with 5 x 10
5
 PFF 
cells. Then electroporation with the program U12 took place. After this treatment 
cells were pipetted with an Amaxa plastic pipette in 1 ml medium to a cell culture 
dish. The next day media was exchanged.  
3.3. Mass cell selection 
Three days after electroporation cells were confluent (around 90%) and were 
harvested. For selection of cells, they were seated with medium containing 
Geneticin (G418; 1.0 mg/ml) on a new cell culture dish. Every two days selection 
medium was changed. After one week of culture all cells had died, which did not 
integrate the antibiotic resistance gene; these cells were floating in the 
supernatant. Successfully transfected cells were able to survive selection and 
formed colonies. The cells were cultured until 90% confluence and then harvested 
and cryopreserved until SCNT was performed.  
4. Vector design  
4.1. Lentiviral vectors  
The described lentiviral vectors (Figure 4) were constructed in the ExperiMed 
laboratory of Chirurgische Klinik und Poliklinik – Innenstadt LMU Munich by 
PD Dr. med Wolfgang Böcker. Head of Experimental Surgery and Regenerative 
Medicine (ExperiMed) laboratories is Prof. Dr. med. Matthias Schieker 
(www.experimed.de). Lentiviral transduction and selection of porcine fetal 
fibroblast cells were performed by Tamara Radic at ExperiMed laboratory. 
Transduced cells carrying the desired constructs were donated to our laboratory to 
produce transgenic offspring by SCNT.  
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Figure 4: Overview of lentiviral vectors  
1) pLenti6-CMV-pRANKL (Bla+) 
 
2) pLenti6-CMV-TetON (Bla+) 
 
3) pLenti6-CMV-TetON-ΔBla (Bla-) 
 
4) pLenti6-CMV-TetON-TREtight-pRANKL (Bla+) 
 
5) CMV-TetOn-TREtight-pRANKL (Neo+) 
 
These figures were a donation of PD Dr. med Wolfgang Böcker.  
BSD: blasticidin-S deaminase (Basticidin 
resistance gene)  
LTR: long terminal repeat 
Pcmv: cytomegalovirus promoter 
pRANKL:  porcine receptor-activator of 
nuclear factor kappa beta ligand  
pTRE tight: Tet-Advanced transactivator 
response element promoter (TARE)  
RRE: Rev-responsive element  
rtTA: reverse tetracycline-controlled 
transcriptional activator (Tet-On) 
NEO: neomycin resistance  
 
The lentiviral vectors starts and ends with long terminal repeats (LTR), which are 
responsible for the regulation of synthesis and processing viral RNA and other 
replicative functions. Another essential part of lentiviral vectors is the Rev-
responsive element (RRE), because REV signaling mediates the export of the 
viral RNA out of the nucleus. The desired genes Tet-On and pRANKL were 
inserted to separate vectors (1–3) and also combined in one vector (4 and 5). 
These genes were controlled by a CMV promoter or the TRE tight promoter. For 
the later selection of cells with transgene integration, the antibiotic resistance gene 
for Blasticidin or Neomycin was introduced (except 3). In the last construct (5) all 
lentiviral elements, like the LTRs and the RRE, were cut out leaving only the 
genes of interest Pcmv-Tet-On and TREtight-pRANKL and additional the 
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Neomycin resistance gene. These assembly changes were applied to adapt the 
lentiviral vector to the Amaxa Nucleofector system. With the donated Tet-On-
RANKL-Neo (5) vector porcine fetal fibroblast cells were transfected in our 
laboratory.  
4.2. Conventional vectors  
The vectors 6 and 7 were designed and constructed by Dr. rer. nat. Nikolai 
Klymiuk in our institute. The Tet-On and RANKL gene were integrated under the 
control of the CAG and the TARE (pTRE tight) promoter. Neomycin and 
blasticidin antibiotic resistance and the polyadenylation signal of the bGH gene 
was added. The poly adenosine tail contributes to the nuclear export, translation 
and stability of mRNA. The antibiotic resistance is needed for further selection of 
cells with stable integration of the desired genes. To avoid possible negative side 
effects of antibiotic resistance genes, loxP sites were introduced. With the enzyme 
Cre recombinase it is feasible to cut out specifically the loxP sites and the gene in 
between is deleted. Both gene constructs were used for cell transfection in our 
laboratory. 
Figure 5: Overview of conventional vectors  
6) CAG-rtTA: lox2 neo® – CAGpr – rtTA ORF – bGHpA 
 
7) TARE-RANKL: TAREpr – RANKL ORF – bGHpA – lox2 bla®  
 
These figures were a donation of Dr. rer. nat. Nikolai Klymiuk. 
bGH: bovine growth hormone gene 
bla: blasticidin resistance  
CAG: CMV early enhancer / chicken beta actin 
promoter 
lox: locus of X-over P1 (lox P site) 
neo: neomycin resistance  
ORF: open reading frame 
pA: (PolyA) polyadenylation signal 
PR: promoter 
RANKL: porcine receptor-activator of nuclear 
factor kappa beta ligand 
rtTA: reverse tetracycline-controlled 
transcriptional activator (Tet-On) 
TARE: Tet-Advanced transactivator response 
element promoter (pTRE tight)  
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5. Procedure of somatic cell nuclear transfer 
Per week, two nuclear transfer experiments were scheduled, one performed on 
Wednesday and the other one on Thursday. Oocyte maturation and cell 
preparation must be exactly timed to fit in the procedure. All produced NT 
embryos were equally mixed and transferred to one or two recipients on Friday.  




































5.1. In vitro maturation of oocytes 
5.1.1. Ovary collection 
Sixty to 90 ovaries per day were collected at a local abattoir and transported to the 
laboratory in phosphate buffered saline (PBS) containing 75 µg/ml potassium 
penicillin G, 50 µg/ml streptomycin sulfate and 0.1% (w/v) polyvinylalcohol 
(PVA) in a warming box under the stable temperature of 36°C to 37°C degrees.  
5.1.2. Oocyte collection  
Cumulus-oocyte complexes (COCs) were collected by aspiration with a needle 
and syringe from ovarian antral follicles of 3.0-6.0 mm in diameter.  
5.1.3. Selection of oocytes 
In a first step all COCs which were visible were collected and washed in Tyrode´s 
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albumin lactate pyruvate (TALP) solution. Only COCs displaying over 3 layers of 
compacted cumulus cells with even cytoplasm were selected and used for further 
experiments. The remaining poor quality and altered COCs were discarded.  
5.1.4. Oocyte maturation  
120 to 180 first grade COCs per day were subsequently cultured in North Carolina 
State University medium-23 (NCSU-23) supplemented with 0.6 mM cysteine, 10 
ng/ml epidermal growth factor (EGF), 10% (v/v) porcine follicular fluid, 75 µg/ml 
potassium penicillin G, 50 µg/ml streptomycin sulfate, 10 IU/ml equine chorionic 
gonadotropin (eCG; Intergonan, Intervet, Germany) and 10 IU/ml human 
chorionic gonadotropin (hCG; Ovogest, Intervet, Germany). The first 22 h they 
were cultured with the hormones eCG and hCG, and then for 20 h without these 
hormones in a humidified atmosphere of 5% CO2 and 95% air at 38.5 °C.  
5.1.5. Denudation of matured oocytes  
After 42 hours culture, the in vitro matured (IVM) oocytes with expanded 
cumulus cells were treated with 1 mg/ml hyaluronidase dissolved in TALP 
medium supplemented with 10 mM Hepes and 0.3% (w/v) polyvinylpyrrolidone 
(PVP) (Hepes-TALP-PVP) and were denuded of cumulus cells by gentle 
pipetting. Oocytes displaying evenly granulated ooplasm and extrusion of the first 
polar body were considered as fully matured and selected for the experiments.  
5.2. Nuclear transfer in vivo experiment 
Somatic cell nuclear transfer (SCNT) was performed using IVM oocytes as 
recipient cytoplasts.   
5.2.1. Enucleation 
Enucleation was performed using a chemically assisted method developed by Yin 
et al. (YIN et al., 2002). Oocytes were exposed to NCSU-23 medium 
supplemented with 0.1 µg/ml demecolcine, 0.05 mM sucrose and 4 mg/ml bovine 
serum albumin (BSA) for 0.5-1 h and subsequently enucleated by aspirating the 
first polar body and the adjacent cytoplasm using a beveled pipette (30 µm in 
diameter) in Hepes-TALP-PVP containing 0.1 µg/ml demecolcine, 5 µg/ml 
cytochalasin B (CB) and 10% FBS. Any protrusions observed on the surface of 
the oocytes were removed along with the polar body.  
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Figure 7: Enucleation  
            
a) Penetration of the zona 
pelucida 
b) Soakage of the first polar 
body and the adjacent 
cytoplasm 
c) Enucleated oocyte 
5.2.2. Donor cell preparation  
Cell cycle of donor cells was synchronized in the G0/G1 stage by serum 
starvation starting 48h before nuclear transfer. On the day of nuclear transfer, 
donor cells were detached from culture dish and singularized by trypsinization. 
Figure 8: Appearance of donor cells just before injection 
 
5.2.3. Donor cell injection  
For cell insertion, round, small donor cells, with a smooth surface and a regular 
looking were selected. One single donor cell per enucleated oocyte was injected 
through the hole in the zona pelucida, originated by enucleation, into the 
perivitelline space.  
Figure 9: Donor cell insertion 
           
a) Introduction of the pipette 
through the enucleation 
hole 
b) Injection of one donor 
cell 
c) Reconstructed NT 
embryo 
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5.2.4. Fusion  
Donor cell-oocyte complexes were placed in a droplet of 280 mM mannitol 
solution (pH 7.2) containing 0.15 mM MgSO4, 0.01% (w/v) PVA, and 0.5 mM 
Hepes and held between 2 electrode needles. Membrane fusion was induced using 
an Electro cell fusion LF101 (NEPA GENE Co. Ltd.) by applying a single direct 
current (DC) pulse (200 V/mm, 20 µs ×1) and a pre- and post-pulse alternating 
current (AC) field of 5 V, 1 MHz for 5 s, respectively. Reconstructed embryos 
were cultured in NCSU-23 for 0.5-1h, followed by electrical activation.  




Reconstructed embryos were washed twice in an activation solution consisting of 
0.3 M mannitol, 50 µM CaCl2, 100 µM MgSO4 and 0.01% PVA (300 mOsm), 
then placed between 2 wire electrodes (1 mm apart) of a fusion chamber slide and 
overlaid with activation solution. A single DC pulse of 150 V/mm was applied for 
100 µs. To suppress extrusion of the pseudo-second polar body, activated oocytes 
were subsequently cultured in a medium containing 5 µg/ml cytochalasin B (CB) 
for 3 h.  
5.2.6. In vitro culture of reconstructed embryos 
The reconstructed embryos were stored for one or two days, until embryo transfer 
took place, in 20-µl droplets of porcine zygote medium (PZM-5) under paraffin 
oil in a plastic Petri dish maintained under a humidified atmosphere of 5% CO2, 
5% O2, 90% N2 at 38.5 °C.  
5.3. Nuclear transfer in vitro experiment  
The procedures of nuclear transfer for in vitro experiments were basely the same 
as in an in vivo experiment, with one exception: the enucleation was confirmed by 
staining cytoplasts with 5µg/ml bisbenzimide (Hoechst 33342). Not completely 
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enucleated oocytes were rejected. Cleavage and blastocyst formation of 
reconstructed embryos were monitored during culture for 7 days. In vitro culture 
of embryos was performed in 20-µl droplets of porcine zygote medium (PZM-5) 
under paraffin oil in a plastic Petri dish maintained under a humidified atmosphere 
of 5% CO2, 5% O2, 90% N2 at 38.5 °C.  
5.4. Embryo transfer  
Six to seven months old prepuberal gilts (hybrids of ―Schwäbisch-Hällisches 
Landschwein‖ and ―Deutsche Landrasse‖) were used as recipients.  
5.4.1. Estrus synchronization 
Estrus synchronization was conducted by oral administration of altrenogest 
(Regumate, Serumwerk Bernburg, Germany) over a 15 day period, followed by 
intramuscular injection of 750 IU eCG, (Intergonan, Intervet, Germany) which 
has a follicle stimulating effect, 24 hours after last gestagen administration. 
Ovulation was induced 3 days later by intramuscular injection of 750 IU hCG 
(Ovogest, Intervet, Germany).  
5.4.2. Endoscopic embryo transfer  
Endoscopic embryo transfer was performed two days after Ovogest treatment. 
Recipients were anesthesized with a combination of 1.2 ml per 10 kg ketamine 
hydrochloride (Ursotamin, Serumwerk Bernburg, Germany) and 0.5 ml per 10 kg 
xylazine (Xylazin 2%, WDT, Germany) intravenously.  
Figure 11: Endoscopic embryo transfer  
   
a) Prepared recipient b) operation field with the 
endoscopic optics (left), 
grasper (middle) and trocar 
(right) 
c) introduction of the embryo 
loaded catheter 
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Recipients were brought into 45° dorsal recumbency, and 53 to 147 embryos were 
transferred laparoscopically in to the right oviduct. 
Figure 12: Introduction of the catheter into the oviduct  
   
a) The right oviduct with inserted trocar b) expansion of the right oviduct through the 
introduced catheter 
6. Pregnancy control and birth  
6.1. Pregnancy control 
Pregnancy status was confirmed by ultrasound examination. These examinations 
were performed at least three times per recipient, the first check (TU1) always 
was scheduled for day 28, the second check (TU2) between day 50 and 70 and the 
third check (TU3) between day 90 and 110 after embryo transfer. Sows were 
classified as pregnant, when liquid filled chambered vesicles in the uterus were 
visible (TU1). At the later stages of pregnancy (TU2 + TU3) also fetuses were 
detected and evaluated.  
6.2. Induction of labor  
If spontaneous birth did not occur until day 117, labor was hormonally induced by 
intra muscular application of 0.7 ml Cloprostenol (Estrumate, Intervet, Germany).  
7. Overview: transgenic pig production via SCNT  
The production schedule of transgenic SCNT pigs with mass cell selection instead 
of single cell clone selection provides the advantage of a shorter culture time and 
less stress of single culture of fibroblasts. The basic difference is that the 
screening step was done after SCNT and not before. Consequently, litters after the 
first round of SCNT represented different cell lines. After screening, a second 
round of nuclear and embryo transfer was necessary to obtain transgenic founder 
animals.  
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Figure 13: Efficient production of transgenic pigs via SCNT (AIGNER et al., 
2010)  
 
8. In vivo doxycycline stimulation 
RANKL overexpression was in vivo stimulated by oral administration of 
Pulmodox® (Virbac Tierarzneimittel GmbH, Bad Oldesloe), with the active 
ingredient doxycyclinhyclat. Pigs were treated with doxycycline at a dosage of 40 
mg/kg/day continuously over 6 days. Plasma blood samples were obtained on day 
0 (before first doxycycline application), on day 3 and day 6 of doxycycline 
treatment. To distinguish the different RANKL plasma levels, ELISAs were 
performed by Tamara Radic at ExperiMed laboratory.  
9. Statistical analysis 
For statistical analysis the software of IBM SPSS Statistics, Version 18.0.0 was 
applied. The design of diagrams was optimized with Microsoft Excel 2010. 
Statistically verifiable relations were tested by bivariate correlations, for this 
purpose the correlation coefficients according to Pearson were calculated. The 
higher the value, the stronger is the correlation with a maximum of 1 and the 
common probability error of α* = 0.05 or α** = 0.01. Interrelationships were 
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pictured in cross-classified tables. Furthermore T-tests with unpaired random 
sampling were performed to test the significance level. Differences were 
considered significant at P < 0.05.  
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IV. RESULTS 
1. Assessment of SCNT and ET   
1.1. Overview of the years 2006 to 2009 
In the year 2006 the technique of porcine somatic cell nuclear transfer was 
established in our laboratory. After the first birth of SCNT piglets obtained from 
wild-type porcine fetal fibroblast cells, SCNT procedures were continued with 
transgenic cells, either produced in our laboratory or obtained from other 
laboratories. The first transgenic SCNT piglets were born on January the 15
th
 
2007. Until the end of 2009, 12880 NT embryos were produced and transferred to 
145 recipients. Transfers resulted in 41 births with a total of 160 piglets, 13 
terminated pregnancies with a total of 75 fetuses, 26 abortions and 65 non 
pregnant recipients. Most of embryo transfers were performed during 2008 and 
2009, accordingly the majority of births occurred during 2008, 2009 and 2010. 
Over the years, number of cultured oocytes rose, but maturation rate (matured 
oocytes/total number of cultured oocytes) declined. Fusion rate (fused 
embryos/total number of reconstructed embryos) and cleavage rate (cleaved 
embryos counted at the day of ET/total number of cultured NT embryos) 
increased. The number of NT embryos transferred during ET ranged from 48 to 
152, but the average number did not differ much over the years. Pregnancy rate 
was varying a lot compared over the years. Abortion rate declined whereas the 
years 2008 and 2009 were almost the same. Although the total number of born 
piglets was rising the average number of born piglets per recipient was almost 
stable, whereas the average number of still born piglets dropped in 2009. Overall 
cloning efficiency mounted and was highest at 2008. All these findings are 
tendencies, because there are too few cases to perform a statistical analysis.  
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Table 3: In vivo SCNT work of the years 2006 until 2009 
Year 2006 2007 2008 2009 Total 
Number of performed 
embryo transfers 
11 13 53 68 145 
Total number of cultured 
oocytes 
1477 1933 13022 18006 34438 
Average maturation rate in % 85 87 79 76 82 
Average fusion rate in % 78 86 89 87 85 
Average cleavage rate of NT 
embryos in % 
78 80 88 90 84 
Total number of NT embryos 
transferred 
896 1121 4885 5978 12880 
Average number of 
transferred NT embryos per 
recipient 
81 86 92 88 87 
Pregnancy rate in % 64 31 60 54 52 
Abortion rate in % 57 50 28 30 41 
Number of birth 2 1 19 19 41 
Number of pregnancy 
stopped 
1 1 4 7 13 
Total number of piglets / 
fetuses 
13 10 100 112 235 
Average number of piglets / 
fetuses per recipient 
4.33 5 5.26 4.31 4.73 
Total number of stillborn or 
degenerated piglets / fetuses 
4 2 20 15 41 
Average number of stillborn 
or degenerated piglets / 
fetuses per recipient 
1.33 1 1.05 0.58 0.99 
Cloning efficiency in % 
(offspring per transferred NT 
embryos) 
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1.2. Outcome of in vivo SCNT procedure 
Of all 169 transgenic SCNT pigs born until June 2010, 37% were healthy and 
showed a normal development, the remaining 63% were lost. These losses can be 
divided in different groups, like still born, early neonatal death, killed by mother 
and lethal disease. The still born piglets died at different stages of pregnancy, but 
mainly they reached the last trimester. Some of the stillborn piglets showed 
abnormalities, but the majority appeared to have a normal development until 
shortly before birth. 
Table 4: Upgrowth of SCNT piglets  





Cases and explanation 
Healthy and normal 
development  
63 (37) - Transgenic SCNT pigs up to three 
years of age until now 
- Produced healthy and transgenic 
progeny  
Still born 39 (23) - Full grown and fully developed 
- Mummification 
- Abnormalities  
Early neonatal death 52 (30) - Severe underweight (< 900g) 
- Weakness, low viability  
- Abnormalities:  Oversize tongue, 
Cleft palates,  Atresia ani 
Killed by mother 11 (7) - Prolonged and laborious birth 
- Nervous sow  
Lethal disease  4 (2) - Malignant hyperthermia syndrome 
- Bacterial meningitis 
 
Most piglets were lost due to early neonatal death of weak and not viable piglets, 
some additionally showed severe underweight. For them it is hard to enforce a 
claim to their siblings and get enough food, especially at the first days. Another 
occurrence were piglets with deformations like oversize tongue and cleft palate. 
For these piglets it is impossible to drink milk, because they cannot produce the 
vacuum pressure needed. Another abnormality which occurred at times was 
contracted tendons in the front legs, but almost all involved piglets survived with 
some assistance. A smaller group was killed by the mother sow. Gilts were used 
as recipients for embryo transfers and it is impossible to predict their future 
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mother qualities. Also most times labor had to be medically induced and in some 
cases birth was prolonged and painful. It has happened that between two piglets 
there was a 24 hour delay. Only few piglets died in the course of a disease. 
1.3. Evaluation in vivo SCNT data 
All descriptive statistical analyses shown in the following are sourced of the in 
vivo SCNT data from 19.06.2006 to 31.05.2010.  
1.3.1. Impact of seasonal change  
The in vivo SCNT experiments were assigned to the four seasons; the date of 
embryo transfer was used for the classification. The months March, April and 
May were classified as spring, June, July and August as summer, September, 
October and November as autumn and December, January and February as 
winter. When in the following seasons are mentioned, they always referred to the 
season in which the embryo transfer took place. During the seasons the maturation 
rate almost showed no variation at all. The pregnancy rate at the first check TU1 
was best in spring (65%) and worst in winter (43%), summer (55%) and autumn 
(54%) had similar rates.  
Table 5: Seasonal changes 
 Spring Summer Autumn Winter 
Number of 
experiments 
31 40 52 28 
Maturation rate % 77 78 80 79 
NT embryos 
transferred  
2917 3504 4485 2378 
Pregnant recipients 
(%) 
20 (65) 22 (55) 28 (54) 12 (43) 
Abortion (%) 7 (35) 11 (50) 5 (18) 4 (33) 
Pregnancy stopped 2 3 5 3 
Birth (%) 11 (55) 8 (36) 18 (64) 5 (42) 
Piglets / Fetuses 49 53 103 38 
Cloning efficiency 
% 
1.68 1.51 2.30 1.60 
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Most abortions occurred, when the embryo transfer was performed during 
summer (50%) and fewest after embryo transfers in autumn (18%). The abortion 
rate during spring (35%) and winter (33%) was almost the same. The highest 
percentage of pregnant recipients giving birth was found in autumn (64%), 
followed by spring (55%), winter (42%) and finally summer (36%) with the 
lowest percentage. The outcome of the SCNT in vivo experiments was that most 
piglets and fetuses were obtained from embryo transfers in autumn and fewest in 
winter, whereas spring and summer were almost equal in this respect. The 
calculated cloning efficiency (offspring per transferred NT embryo) revealed that 
clearly autumn was the best and the rest of season were almost alike, with the 
summer showing the worst performance of all.  
Figure 14: Seasonal influence during course of pregnancy 
 
The influence of the seasons differed during the course of pregnancies. At the first 
pregnancy check (TU1), spring had the highest and winter the lowest pregnancy 
rate, autumn and summer were close together in between of them. During the 
ongoing gestastion it was reaveled that in all seasons pregnancies were lost, 
especially the pregnancy rate of summer dramatically dropped. This phenomenon 
was seen in the second pregnancy check (TU2) and even more clearly at the last 
pregnancy check (TU3). By the end of gestastion, the best results were obtained in 
spring and autumn, and the worst in winter and summer. 
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Figure 15: Seasonal influence on embryo transfer outcome 
   
Pregnancies finished to term Abortion 
 
Looking at the number of pregnancies finished to term at the differnt seasons, the 
autumn was outstanding. In autumn the range between birth and no birth was the 
highest, that means almost all sows wich became pregant during autumn also 
finished it succesfully. After the autumn, the spring had the second best birth rate. 
In winter the number of birth and no birth was almost equal. The only season 
where it was opposite down and more pregancies were lost than finished was the 
summer. During the seasons the number of abortion conducted almost reverse to 
the pregnancies finished to term. The main diffenerence is that stopped 
pregnancies for gaining fetuses, were counted as no abortion. It was revealed 
again that the autumn is the most eye-cathing season, with fewest abortions, then 
the spring and winter follows. In the summer the number of abortion and no 
abortion are equal, in all other seasons the number of no abortion is higher then 
the number of abortion.  
1.3.2. Effects of different SCNT donor cell treatment 
Here it is distinguished between donor cells which were only treated in our 
laboratory and donor cells which were donated from several other laboratories. 
Cells from our laboratory were used in 74 in vivo experiments, other cells 
contributed to 77 experiments.   
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Figure 16: Performance of different donor cells during pregnancy 
   
First pregnancy check TU1 Second pregnancy check TU2 Last pregnancy check TU3 
 
At the first pregnancy check TU1, both donor cell groups had very similar 
pregnancy rates. As the pregnancies went on the two groups began to alter. At the 
second check TU2 there were already more non pregnant recipients of donor cell 
of other laboratories, compared with our donor cells. This trend continued also at 
the last check TU3. 
Figure 17: Comparison of different donor cells performance during the 
course of pregnancy until birth. 
 
Pregnancy rates and total birth rates (pregnant recipients or occurance of birth 
divided by total number of recipients) were also calculated to elucidate the 
changes of donor cell perfomance in the course of pregnancy. Cells originated 
from other laboratories started with the highest pregnancy rate, but subsequently 
dropped dramatically. On the other hand cells treated only in our laboratory 
started second best, but showed a minor decline in following pregnancy rates. 
Finally our donor cells resulted in a noteable higher overall birth rate than donor 
cells of other laboratories.  
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Figure 18: Birth and abortion rate in different donor cells 
   
Total birth rate Pregnancies finished to term Abortion 
 
The pregant recipient birth rate exposed a remarkable discrepancy between the 
donor cells obtained from other laboratories and donor cells orignated from our 
laboratory. Statistical analysis was performed and revealed a significant 
correlation and a significance level of 0.006 (T-test). Donor cells for SCNT 
procedure treated exclusively in our institue had a significantly higher chance, that 
pregancy results in birth. The abortion rate shows the same phenomenon just in 
reverse. When donor cells from our laboratory were used, there are significantly 
fewer abortions than cells from other source. Not only birth, but also stopped 
pregnancies with obtained fetuses were counted as no abortion.  
1.3.3. Different time periods of embryo culture 
To examine the loss of oocytes from beginning of culture until fusion step of 
SCNT, the ratio of cultured oocytes to fused embryos was calculated. A ratio of 
100% would mean no loss of oocytes.  
Figure 19: Influence of oocytes loss during SCNT procedure on Wednesday 
   
Pregnancies finished to term Abortion 
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On Wednesdays the ratio oocytes/fused embryos had a significant impact on the 
outcome of pregnant recipients. Most pregnancies persisted until the end and 
resulted in birth at a ratio better than 50% and under this value it was the other 
way around. A similar behavior in reverse was found in the abortion rate. 
 
Figure 20: Influence of oocytes loss during SCNT procedure on Thursday 
   
Pregnancies finished to term Abortion 
 
Thursday’s ratio of oocytes/fused embryos showed neither connection to the birth 
of pregnant recipients nor to the abortion rate. The loss of oocytes during nuclear 
transfer process on Thursdays had no significant impact on the outcome like birth 
or abortion. Oocytes and NT embryos for experiments on Wednesday and 
Thursday were treated exactly the same way from in vitro maturation until fusion 
step of SCNT. The only difference occurred in diverging in vitro culture time of 
NT embryos. NT embryos produced on Wednesday underwent 2 days of culture 
and NT embryos of Thursday had only a one day in vitro culture. Subsequently 
NT embryos of both days were mixed and transferred together into recipient sows 
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Table 6: SCNT performed only on Wednesday or on Thursday  
 
Day two NT embryos 
transferred 
Day one NT embryos 
transferred 
number of experiments 12 15 
cultured oocytes 1764 2193 
maturation rate in % 79 78 
number of transferred 
embryos 
864 1284 
pregnant recipient (%) 6 (50) 8 (53) 
Birth (%) 2 (33) 4 (50) 
pregnancy stopped 2 (33) 0 
Abortion (%)  2 (33) 4 (50) 
piglets/ fetuses 20 20 
still born 1 1 
 
Here are all in vivo SCNT experiments enlisted performed only on one day per 
week and therefore with different time periods of in vitro culture of embryos. Day 
one or day two embryos were transferred always on Fridays. In these cases the NT 
embryos could not be mixed, because only a single experiment was performed in 
these according weeks. Comparing both days ouctome it was visible that there are 
almost alike, total number of piglets and fetuses was even the same. Here it was 
elucidated, that SCNT embryos produced on different days both have a chance to 
develop to full term, although they are transferred in a different stage of 
development.  
1.3.4. Number of transferred NT embryos per recipient 
The number of transferred NT embryos ranged between 48 and 152, but in the 
main there were 81 to 90 NT embryos transferred per recipient. At the first 
examination of pregnancy status (TU1) no significant correlation between 
numbers of transferred embryos and occurrence of pregnancy could be found. Still 
there was a slight tendency, that recipients with over 100 transferred NT embryos 
had a better chance to become pregnant, whereas in recipients with under 100 
transferred embryos the chance was almost equal.  
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Figure 21: Impact of number of transferred NT embryos on pregnancy 
(TU1+TU2)  
   
First pregnancy check TU1 Second pregnancy check TU2 
 
This tendency transformed during the course of pregnancy to a significant 
correlation. At the following pregnancy checks TU2 and TU3 it showed that when 
more than 100 embryos were transferred there was a significantly better chance of 
an enduring pregnancy. On the other hand, when under 70 embryos were 
transferred there was a significantly lower chance for a continuing pregnancy.  
Figure 22: Number of transferred embryos and last pregnancy check and 
total birth rate  
   
Last pregnancy check TU3 Total birth rate 
 
 The total birth rate behaved almost the same like the last pregnancy check TU3, 
there were only very few pregnancies lost in the last trimester.  
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Figure 23: Influence of the number of transferred NT embryos on birth of 
pregnant recipients and abortion 
   
Pregnancies finished to term Abortion 
 
The trend visible during course of pregnancy also turned up in the birth of 
pregnant recipients and in the abortion rate and even clarified this trend. When 
over 100 NT embryos were transferred almost no pregnancies were lost and when 
under 70 NT embryos were transferred almost no pregnancy resulted into birth.  
2. Production of cloned RANKL transgenic pig   
2.1. In vitro SCNT embryo development competence of different cell 
lines 
Before using new cell lines for in vivo SCNT experiments, they are tested for 
their in vitro development ability. At first wild-type porcine fetal fibroblast cell 
lines (PFF 06 and PFF 26) were tested, which served as basic cell lines for later 
transfection or transduction. The cell lines CMV RANKL, rtTA Bla+ and rtTA 
Bla- were transduced with lentiviral vectors at ExperiMed laboratory. All these 
cell lines showed the ability to generate blastocysts after SCNT. 
Figure 24: CMV RANKL hatching blastocysts 
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Table 7: In vitro test of wild type and lentiviral transduced cell lines 
donor cell Experiments NT embryos 




Wildtype cell lines 
PFF
1
 06 3 123 50 41 
PFF
1
 26 1 30 4 13 















 - 2 46 12 26 
1) PFF- porcine fetal fibroblast 
2) cmv- cytomegalovirus promoter 
3) RANKL- receptor-activator of nuclear factor kappa beta ligand 
4) rtTA- reverse tetracycline transcriptional activator (Tet-On) 
5) Bla- Blasticidin 
 
2.2. In vivo RANKL and Tet-On SCNT experiments  
The different transgenic cell lines were established through two methods. In the 
beginning, the cells were modified via lentiviral transduction at the ExperiMed 
laboratory of Chirurgische Klinik und Poliklinik – Innenstadt LMU Munich (cell-
lines: CMV-RANKL, Tet-On Bla+, Tet-On+RANKL+Bla). In another approach, 
cell lines were transfected by the Amaxa system in our laboratory (cell lines: Tet-
On+RANKL+Neo, Tet-On+CAG promoter, 9894+TARE RANKL). For the 
production of the transgenic SCNT pigs 17 embryo transfers were performed. The 
pregnancy of 11 recipients and so a pregnancy rate of 64.71% was observed. 
These pregnancies resulted in one interruption with 4 obtained fetuses, 6 births 
with 25 born piglets and 4 abortions with an abortion rate of 36.36%. The overall 
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Table 8: In vivo RANKL and Tet-On SCNT experiments 













A) lentiviral transduction  
RANKL CMV-promotor 1 94 No       
RANKL CMV-promotor 2 53 Yes Abortion     
RANKL CMV-promotor 3 75 No       
Tet-On Bla+ 4 61 No       
Tet-On+RANKL+Bla 5 80 Yes Abortion     
Tet-On+RANKL+Bla  6 80 No       
B) amaxa transfection  
Tet-On+RANKL+Neo 7 110 Yes Stopped 4 1 
Tet-On+RANKL+Neo 8 87 No       
Tet-On+RANKL+Neo 9 87 No       
Fetus 3 recloning  10 103 Yes Birth 2 2 
Fetus 3 recloning  11 82 Yes Abortion     
Fetus 3 recloning  12 82 Yes Abortion     
Tet-On + CAG pormoter 13 147 Yes Birth 6 0 
9894+TARE RANKL 14 110 Yes Birth  5 2 
9894+TARE RANKL 15 94 Yes Birth 4 1 
9894+TARE RANKL 16 83 Yes Birth 5 3 
9894+TARE RANKL 17 83 Yes Birth 3 2 
 
(A) Lentiviral transduction: Cells carrying the RANKL construct under control 
of the ubiquitous CMV promoter were used as donor cells for SCNT and were 
subsequently transferred to three recipients. One pregnancy could be detected but 
was lost before second ultrasound examination. Nuclear transfers of Tet-On and 
Tet-On-RANKL-Bla+ cells also leaded to one pregnancy, it was aborted as well. 
(B) Amaxa transfection: Donor cells transfected with a vector containing the 
Tet-On and the RANKL-TARE construct were used for 3 in vivo-experiments. 
One pregnancy could be established and was terminated on day 41 to obtain 
fetuses. Fetus 3 was recloned in 3 experiments, which lead to the birth of 2 
stillborn Tet-On RANKL piglets. For a two-step strategy, the transactivator 
element Tet-On was introduced into a fetal fibroblast cell line. After SCNT, the 
reconstructed embryos were transferred into one recipient. Pregnancy resulted in 
six Tet-On transgenic piglets, which were sacrificed to obtain individual cell lines 
carrying the transactivator gene. Fetal cell lines were screened for expression of 
the Tet-On gene. After transfection with the RANKL construct containing a 
transactivator responsive element, a second round of SCNT was performed and 
embryos were transferred to 4 recipients. All of them became pregnant and 
finished to term, and altogether 17 piglets were born. 
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2.2.1. Recovery of Tet-On+RANKL+Neo fetuses 
The pregnancy of recipient sow NT3 was terminated at day 41 after embryo 
transfer to gain the SCNT fetuses. Four fetuses could be obtained, of which three 
showed a normal development and one was already degenerated. Cell cultures 
were established from all fetuses, but only cells of Fetus 1, Fetus 2 and Fetus 3 
were viable. 
Table 9: Data of Tet-On+RANKL+Neo Fetuses 
name of construct Tet-On+RANKL+Neo 
No. of experiment 7 
Date of embryo transfer 20.06.2008 
No. of recipient sow NT 3 
Date of birth 30.07.2008 
No. of piglets / fetuses 4  
Degenerated 1 
 
Genotyping elucidated that Fetus 2 and Fetus 3 were carrying the Tet-On and 
RANKL gene and Fetus 1 did not. In the fetuses number 2 and 3 mRNA and 
protein of Tet-On could be detected. Expression of RANKL was only visible in 
Fetus 3, but this expression did not alter under in vitro doxycycline stimulation. 
These analyses were all performed by Tamara Radic at ExperiMed laboratory.  
Figure 25: Tet-On+RANKL+Neo fetuses  
             
a) Fetus 3: normal developed b) Fetus 4 
2.2.2. Recloning of Fetus 3 
The piglets, number 9878 and number 9879, were both born dead after a 
prolonged time of labor. Because these piglets probably had been already dead 
some time before labor started it was impossible to perform a complete analysis. 
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Table 10: Data of piglets recloned from Fetus 3 
Name of construct Fetus 3 recloning 
No. of experiment 10 
Date of embryo transfer 13.03.2009 
No. of recipient sow NT 44 
Date of birth 08.07.2009 
No. of piglets / fetuses 2 
Stillborn 2 
 
From the established cell lines of each piglet it could be elucidated that both were 
expressing Tet-On and RANKL at the mRNA level. The RANKL expression of 
these cell lines could not be stimulated by in vitro doxycycline administration. 
These in vitro tests were accomplished by Tamara Radic at ExperiMed laboratory. 
2.2.3. Birth of Tet-On+CAG piglets 
Out of the Tet-On + CAG transgenic cell line after SCNT procedure and embryo 
transfer 6 living piglets were born, of which each was a donator for a porcine 
kidney cell line. Two piglets died within 2 days after birth and a third piglet died 2 
weeks later. The remaining 3 piglets were sacrifized to obtain samples for the 
analysis and the cell culture. 
Table 11: Data of Tet-On+CAG piglets 
Name of construct 
Tet-On + CAG 
promoter 
No. of experiment 13 
Date of embryo transfer 27.03.2009 
No. of recipient sow NT 45 
Date of birth 21.07.2009 
No. of piglets / fetuses 6 
Stillborn 0 
Early neonatal death 3 
Normal development 3 
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Only from piglet number 9893 we could not gain any living cells. The following 
analysis steps revealed that all piglets were carrying the Tet-On gene. All 
individual cell lines were transfected with the TARE RANKL gene and screened 
for best induction after in vitro doxycylin treatment. It appeared that the cell line 
of piglet 9894 transfected with TARE RANKL showed the best induction after 
doxycylcin administration and additionally this cell line showed almost no basal 
expression of RANKL. All mentioned screening and analysis steps were 
performed by Tamara Radic at ExperiMed laboratory.  
Figure 26: Piglets of NT45 (piglets 9891 – 9895) 
            
 
2.2.4. Birth of Tet-On 9894 + TARE RANKL piglets (two step strategy) 
The kidney cell line of the Tet-On transgenic piglet 9894+TARE RANKL was 
chosen for further experiments. SCNT embryos reconstructed from this cell line 
were transferred to 4 recipients, which all finished to term. The total outcome was 
17 born piglets of which 8 were still born. Unfortunately, the majority of these 
piglets were lost during the first days after birth. Only two survived and showed a 
normal development. Genotyping revealed that one of these two piglets carried 
the TARE RANKL gene (piglet 9961). Most of the other piglets did not reach the 
end of the first week, but one piglet also died after 24 days. These piglets 
displayed a low viability and some of them had severe underweight. Additional 
the weakness of piglets leaded to failure of milk production of recipient sow 
NT81 and NT84. 
IV. Results     63 
Table 12: Data of 9894+TARE RANKL piglets 
No. of experiment No. 14 No.15 No. 16 No. 17 
Date of embryo transfer 30.10.2009 06.11.2009 13.11.2009 13.11.2009 
No. of recipient sow NT 79 NT 81 NT 83 NT 84 
Date of birth 23.02.2010 02.03.2010 09.03.2010 08.03.2010 
No. of piglets / fetuses 5 4 5 3 
Stillborn 2 1 3 2 
Killed by mother 0 1 0 0 
Early neonatal death 1 2 2 1 
Normal development 2 0 0 0 
 
Figure 27: Genotyping of 9894+TARE RANKL piglets 9958-9972 
 
 
At genotyping the following piglets were tested positive for TARE RANKL; litter of recipient 79: 
9958, 9961 and 9962; litter of recipient 81: 9963 and 9964. No signal was found in the piglets 
9959, 9965 and 9966.  
 
Genotyping PCR revealed that the piglets (9967- 9972) of recipient 83 and 84 were carrying the 
TARE RANKL gene.   These figures were a donation of Dr.rer.nat. Nikolai Klymiuk 
CAG: CMV early enhancer / chicken beta actin 
promoter  
WT  LR: wild-type landrace pig 
RANKL: receptor-activator of nuclear factor 
kappa beta ligand 
TARE: Tet-advanced transactivator response 
element promoter (TRE tight)  
TA: reverse tetracycline-controlled 
transcriptional activator (Tet-On) 
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Only in recipient sow NT79 piglets were strong and developed in a regular 
schedule. One reason could be that in this sow no interference during labor was 
necessary and she displayed right away good mother qualities. All other recipients 
(NT81, NT83 and NT84) had a prolonged time of labor and piglets could be only 
developed through manual help. Recipient sow NT81 killed one of its piglets by 
biting it. 
Figure 28: Piglets of NT79 (piglets 9959 and 9961) 
 
After weaning RANKL overexpression was stimulated by oral doxycycline 
administration over 6 days. The transgenic pig number 9961 carrying the Tet-On 
and the TARE-RANKL gene displayed an induction of RANKL expression at day 
3 and day 6 of doxycycline treatment. The wild-type control which does not carry 
the TARE-RANKL gene showed only a basal expression of endogenous RANKL. 
The TARE-RANKL transgenic pig had a fivefold higher RANKL blood plasma 
level after doxycycline stimulation than the age matched wild-type control.  
 
Figure 29: Doxycycline-inducible expression of sRANKL 
 
wt: wild-type pig number 9959 
tg: transgenic pig number 9961 
Conc.: concentration in the blood plasma  
d: day 
This figure was a donation of Tamara Radic  
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V. DISCUSSION 
1. SCNT over the years 2006 – 2009 
In the years 2006 and 2007 we were occupied by establishing and improving the 
routine schedule of in vivo SCNT experiments and embryo transfers. During these 
two years only few experiments were performed and the outcome was only 
moderate. But starting with 2008 the number of cases multiplied by 5 times and 
SCNT was performed on a regular and professional basis. The effect showed in 
the number of born piglets and obtained fetuses, additionally the overall cloning 
efficiency was rising, too. The handling of SCNT embryos during 
micromanipulation and in vitro culture slowly improved. This enhancement 
became visible through the continuously elevating fusion and cleavage rate of 
embryos. Similar observations were noted by C.L. Keefer; disposing the thesis 
that better results were obtained of groups which conduct somatic cell nuclear 
transfer on a regular and consistent basis (KEEFER, 2008). Over the years 2006 
until 2009 our average cloning efficiency varied between 0.89% and 2.05%, and 
was thus in the standard range among swine somatic cell nuclear transfer practice 
of 0.5% – 5.1% offspring per transferred SCNT embryos (DAI et al., 2002; 
KUROME et al., 2008; PETERSEN et al., 2008).   
2. Outcome of transgenic porcine SCNT embryo transfers 
There was not only a hazard of losing SCNT fetuses during pregnancies, but also 
a great deal of SCNT piglets died shortly after birth. These cumulative losses 
during all stages of development were one major reason for the low overall 
cloning efficiency; this phenomenon was found also in other groups (PARK et al., 
2005; KISHIGAMI et al., 2008). For example Park et al. reported in detail about 
40 somatic cell cloned piglets, out of which 5 (12.5%) were stillborn, 22 (55%) 
died suddenly during the first week of life and 12 (30%) were healthy (PARK et 
al., 2005). Our outcome of SCNT piglets were in total 169 born piglets, of which 
39 (23%) were stillborn, 52 (30%) were lost in an early neonatal stage and 63 
(37%) were healthy and showed a normal development. These results were 
comparable to the findings of Park et al. implementing that our high number of 
losses among SCNT piglets is due to the cloning procedure. It was often discussed 
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that the emergence of high numbers of abnormalities and the elevated mortality 
rate of SCNT embryos and piglets is due to reprogramming failures and 
epigenetic imprinting of the adult donor cells (JAENISCH et al., 2005). In this 
context there were reports of altered gene expression of SCNT offspring and extra 
embryonic tissue (CHAE et al., 2009; TIAN et al., 2009). But the exact 
mechanism of nuclear remodeling and reprogramming after SCNT still needs to 
be clarified (ZHAO et al., 2010). As long as this issue is not fully decoded, one 
has to resign to the fact that somatic cell cloning has some detrimental side effects 
visible in low overall efficiency and a high mortality rate in all developmental 
stages. Nevertheless, for the generation of transgenic pigs this is so far the most 
efficient and reliable technique (VAJTA et al., 2007). 
3. Statistical analysis 
3.1. Experimental setup 
In our in vivo SCNT trials the main focus was laid on the production of transgenic 
piglets. Therefore we conducted experiments also under unfavorable conditions. 
Some recipient sows reacted poorly to hormonal synchronization and in the 
absence of a practical alternative these recipients were used anyway. In some 
weeks, oocyte in vitro maturation rate was noticeably depressed, additionally the 
amount and appearance of donor cells varied in each batch. The resulting NT 
embryos showed not only diversity in number but also in quality. Nevertheless, all 
reconstructed NT embryos were transferred, so that even a minimal chance of 
success is not wasted. This however caused a high level of variation among our 
results.  
3.2. Seasons  
Although pigs are known for their seasonally varying fertility, we could not find a 
significant correlation between different seasons and our nuclear transfer and 
embryo transfer data. There was only a tendency for a ranking of seasons visible, 
outstanding the autumn was best performing, followed by spring and winter and 
finally the summer was worst. The group Koo et al. also compared pregnancy rate 
and delivery rate of their porcine SCNT in vivo experiments throughout the 
different seasons. The mentioned seasons always referred to the date of embryo 
transfer. They recorded that the highest pregnancy rate was in the autumn group, 
although in the delivery rate spring was significantly higher than autumn. Their 
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winter group showed the worst performance in both pregnancy and delivery rate 
(KOO et al., 2009). The findings in our in vivo experiment were slightly 
divergent. The highest pregnancy rate had our spring group and the lowest our 
winter group. The fewest losses during pregnancy were recorded when embryo 
transfer was done in autumn and the highest losses came from the summer group. 
This high abortion rate of our summer group could be caused by seasonal 
infertility which is also found in conventional domestic pigs. There are reports of 
increase in the number of sows returning to estrus in the summer-autumn period 
and autumn abortion syndrome in domestic pig production (BERTOLDO et al., 
2009). That means pigs inseminated during the summer months have a higher 
abortion rate later on, which confirmed our findings. So the best overall cloning 
efficiency was recorded in the autumn group. The group of Koo et al. assigned the 
spring as the season which showed best results after embryo transfer. Also there 
were no piglets born in their winter group (KOO et al., 2009). In our case we 
recorded birth of piglets from embryo transfers during the winter months, 
although the pregnancy rate was quite low. This could be due to the different 
embryo transfer procedures. Our method of embryo transfer was with endoscopic 
devices and they did a surgery with relocation of the uterine tract outside of 
abdominal cavity. Additionally they had no heatable environment at the pig 
stables to carry out their surgery (KOO et al., 2009), in contrast in our faculty we 
had a room which could be heated during winter time. The sudden drop of 
temperature surely has a detrimental effect on porcine SCNT embryos. Another 
finding was that the in vitro maturation rate of oocytes from slaughtered 
prepubertal sows almost did not differ according to the seasons, meaning that the 
seasons had a bigger influence on the recipient sows than on the in vitro matured 
oocytes gained at the abattoir. Unfortunately the variability was so high and the 
number of cases was too low that no significant correlations could be found. 
Probably there will be a significant correlation if more cases are available in the 
next years. One reason for the low variation of fertility throughout the year is that 
pigs were housed in standardized climate and nutrimental conditions.  
3.3. Different treatment of donor cells  
Origin and history of cells for nuclear transfer had an impact on the duration of 
pregnancies and therefore viability of the SCNT fetuses. Cells which were only 
treated in our laboratory had an in vitro culture period as short as possible to 
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prevent side effects of the artificial living conditions. This was achieved by 
applying mass selection after transfection and no single clone selection. 
Especially fibroblast cells hardly tolerate solitary culture conditions and when 
accompanied by the selection pressure they can bear defects afterwards. In 
contrast, the mass cell selection procedure is less harmful to the cells. This 
resulted in a better donor cell quality and improvement of in vivo SCNT outcome. 
The resulting piglets of one litter represented different cell clones with different 
integration and expression patterns. Thus, it was possible to establish several 
transgenic pig founder lines of one single in vivo SCNT experiment. The main 
disadvantage of mass cell selection is that cells not carrying the desired genes 
could slip through the selection step and result to nontransgenic SCNT piglets. In 
fact the percentage of non-transgenic SCNT piglets derived from mass cell 
selection was quite low, indicating that selection for two passages is sufficient to 
have almost all cells stable transfected. Cells donated from other laboratories 
underwent different culture conditions and handling by various people. 
Additionally all cells of other origin needed transportation either frozen in liquid 
nitrogen or fresh in a culture bottle. All these factors could influence the cell 
quality and it turned out that there was a significantly different abortion rate of 
SCNT embryos generated with cells produced in our lab vs. cells provided by 
collaboration partners. The developmental competence test of porcine wild-type 
cell lines revealed that even cells treated exactly in the same manner and with no 
genetic modification showed a different performance. That means each cell line 
has its individual capacity to successfully serve as donor cell for the nuclear 
transfer procedure. But nevertheless the donor cell treatment and therefore cell 
quality at the time point of nuclear transfer had a tremendous impact on the 
outcome of the in vivo SCNT experiments. One reason for these diverging 
performances could be found in different epigenetic imprinting or other changes 
in the donor nuclei. To form a viable embryo the donor cell has to accomplish 
various gene expression changes involving epigenetic modification and chromatin 
remodeling. Every malfunction during these events can have detrimental effects 
on the SCNT embryos and piglets (MAGNANI et al., 2008; ZHAO et al., 2010). 
A long time of in vitro culture and improper handling of donor cell could lead to 
alterations in the nucleus, which have a negative impact on the development 
capacity of SCNT embryos.  
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3.4. Different time span of in vitro culture of SCNT embryos  
In our schedule of nuclear transfer and embryo transfer regularly two experiments 
per week on Wednesday and Thursday are performed and from both experiments 
embryos are cultured until Friday. NT embryos of both experiments were mixed 
in equal shares and transferred together into one or two recipients. That means 
that NT embryos from Wednesday have a one day longer time span of in vitro 
culture before embryo transfer. The disadvantage of our routinely sequence of 
operations is that after mixing the NT embryos before embryo transfer it is 
impossible to distinguish between NT embryos of Wednesday or Thursday. So 
there was no final proof which NT embryos (Wednesday or Thursday) maintained 
through gestation and resulted in piglets. When NT embryos were not mixed, 
because only one experiment per week was performed, there was no difference in 
pregnancy or abortion rate. Although NT embryos underwent either one or two 
days of in vitro culture before they were transferred on Fridays, in vivo 
experiments on Wednesdays and Thursdays had a very similar outcome. In other 
groups a 24 h delay of estrus synchronization status and development stage of 
SCNT embryo resulted in a significant alteration in pregnancy and delivery rates. 
It was postulated that an asynchrony between the reconstructed embryos and the 
recipients (pre-ovulation status) had a positive influence on the cloning efficiency 
in pigs. The authors reasoned this phenomenon by an improvement of the uterine 
environment for embryos that were delayed in development compared with their 
in vivo produced counterparts (PETERSEN et al., 2008; KOO et al., 2009). 
Interestingly when in vivo derived embryos were transferred already a recipient 
asynchrony of 48 hours resulted in the degeneration of all embryos (GEISERT et 
al., 1991).  
3.5. Number of transferred SCNT embryos 
Although it occurred that a recipient gave birth to 3 piglets after transfer of only 
62 NT embryos, the chances are significantly higher as more embryos are 
transferred per recipient. The best chances of a successful pregnancy outcome 
were achieved with over 100 NT embryos per recipient and the worst chance with 
fewer than 70 NT embryos transferred. This highlights that during pregnancy 
most NT embryos are lost and only around 1- 5% of the embryos transferred 
survive until birth. Therefore this high number of embryos per recipient seems to 
be necessary unless the developmental capacity of SCNT embryos improves 
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greatly. Additionally, in the pig at least four viable conspectuses are needed to 
ensure the onset of early pregnancy (POLGE et al., 1966). On account of this it is 
still gold standard to transfer high numbers of porcine NT embryos (50-150 or 
even more) into each recipient (VAJTA et al., 2007; PETERSEN et al., 2008). 
Interestingly, in our experiments the number of transferred embryos was not so 
important to establish a pregnancy. At the first pregnancy check there was no 
significant relation between occurrence of pregnancy and number of transferred 
NT embryos. But embryo number had a significant influence on later positive 
pregnancy controls. An explanation for this phenomenon could be that at the first 
pregnancy check also parthenogenetic embryos could be detected. It was reported 
that they can develop to at least the limb-bud stage at day 29 and then they 
subsequently degenerate (KURE-BAYASHI et al., 2000). In our SCNT procedure 
we conducted blind enucleation to avoid the unnecessary and harmful UV light 
detection step. So it is possible that some of the transferred NT embryos had a 
remaining nucleus of the oocytes and underwent parthenogenesis. Signaling of 
parthenotes is adequate to maintain early pregnancy until around day 29 
(KAWARASAKI et al., 2009). But just as well the incidence of lost pregnancies 
between first and second pregnancy check could be also caused by the low 
developmental capacity of SCNT embryos.  
4. Production of transgenic Tet-On and RANKL pigs  
First attempts to generate piglets, carrying the RANKL construct under control of 
the constitutively active CMV promoter, resulted in a single pregnancy, which 
was aborted later on. Transgenic mice with constitutive and ubiquitous 
overexpression of sRANKL all died few days before birth. When the 
overexpression took place exclusively postnatal, most transgenic mice grew up to 
be adult and became fertile. It was postulated that sRANKL overexpression 
during late fetal stage had lethal consequences (MIZUNO et al., 2002). In our case 
we obtained no piglets with constitutive and ubiquitous RANKL overexpression, 
yet we only conducted three embryo transfers. The descried abortion could be 
accounted as a common event, which we observed in a similar rate in other in 
vivo SCNT trials. Because it was impossible to exclude a harmful effect of 
RANKL overexpression during fetal development, we additionally integrated a 
controllable gene expression system (Tet-On). This should enable a switch on of 
RANKL expression at any desired time point (SUN et al., 2007; STIEGER et al., 
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2009). During the further approach it was impossible to obtain any offspring out 
of lentiviral transduced donor cells, although they supported in vitro formation of 
blastocysts. In our studies it appeared that cell lines, which had been transfected in 
our own laboratory, displayed a better performance as donor cells for in vivo 
SCNT experiments. So a change of strategy took place and subsequent donor cells 
were all only treated in our laboratory. The results of the production of a double 
transgenic pig in only one step of transfection and SCNT resulted in 4 fetuses and 
2 stillborn piglets after recloning of a transgenic fetus. Unfortunately hardly any 
doxycycline in vitro induction was detectable in this Tet-On+RANKL+Neo 
double transgenic fetuses and the recloned piglets. Therefore a new approach was 
applied in which the Tet-On and RANKL genes were introduced step by step. In 
the first round of transfection and SCNT Tet-On transgenic piglets were created. 
Screenings for the highest level of Tet-On expression and the best inducibility of a 
subsequently transfected TARE-RANKL expression construct were performed 
under in vitro cell culture conditions. Best performance showed the cell line 
derived from the Tet-On piglet number 9894 and transfected with TARE RANKL. 
Subsequently this cell line was the donor for the next SCNTs and resulted in the 
birth of double transgenic piglets. Until today there is no published report about a 
transgenic pig carrying the Tet-On inducible gene expression system. In mice 
several transgenic mouse models with controllable gene expression via 
doxycycline administration were already established (KISTNER et al., 1996; 
ZHU et al., 2002; BACKMAN et al., 2009; RAO & MONKS, 2009; SONG et al., 
2009). So we produced the first piglets which exhibited functional Tet-On and 
also showed inducible expression of the desired gene. Future examinations will 
reveal what impact long time overexpression of RANKL has on piglet number 
9961 originated of Tet-On 9894+TARE RANKL cell line. This piglet may 
develop an osteoporotic phenotype comparable to the human status of disease. In 
7-8 months old mice overexpression of sRANKL resulted in a significant 
deprivation of the femur bone mineral density, due to an enhanced 
osteoclastogenesis (MIZUNO et al., 2002).  
5. Conclusion  
In the continuing working processes our findings are integrated if possible. The 
aim is to transfer at least 100 NT embryos per recipient. We changed embryo 
transfer regime and recipient sow synchronization. Now NT embryos are 
VI. Discussion      72 
transferred on the same day as nuclear transfer takes place, meaning directly on 
Wednesdays and Thursdays. Estrus synchronization is shifted so that sows are in a 
pre-ovulation stage at embryo transfer, corresponding to research results of other 
groups (PETERSEN et al., 2008; KOO et al., 2009). Other laboratories who want 
to donate cells for nuclear transfer procedures, we offer a list of recommendations 
for treatment and handling of donor cells.  
After the successful in vivo induction of RANKL expression of the Tet-On 9894+ 
TARE RANKL pig, it will serve as founder for a transgenic pig line by recloning 
and natural mating. If an osreoporotic phenotype can be induced, this novel model 
will serve for fracture studies in collaboration with surgeons to elucidate the 
influence of the osteoporosis disease state on the healing processes.   
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VI. SUMMARY 
Inducible expression of RANKL in transgenic pigs under the control of the 
Tet-On system 
Because of the tremendous need for transgenic large animal models for human 
diseases, the process of SCNT is a crucial step in transgenic pig production. In our 
study, we evaluated the particular steps during the production for their impact on 
the efficiency of cloning transgenic pigs. For this purpose, statistical analysis was 
performed for all SCNT data from the years 2006 until June 2010. The RANKL 
transgenic osteoporosis model was chosen for an example for the production steps 
needed to finally achieve a disease model, to elucidate pitfalls and chances of 
SCNT procedure. In total 151 in vivo SCNT experiments using different 
transgenic cell lines were carried out, resulting in 243 piglets and fetuses. 
Statistical analysis revealed that donor cells treated exclusively in our laboratory 
had a significant better birth rate than donor cell originated of other laboratories. 
Furthermore, there was a significant relation between number of transferred NT 
embryos and later pregnancy checks, birth rate and abortion rate. The more NT 
embryos were transferred, the more pregnancies finished to terms. It was also 
elucidated that in our studies a different in vitro culture time of 24 or 48 hours had 
no significant impact on the outcome like pregnancy or birth rate. Seasonal 
changes during the years had no significant influence on pregnancy rate, birth or 
abortion. But there was a strong tendency that autumn showed best performance 
of all seasons, and most pregnancies were lost after embryo transfers during the 
summer. All these findings will be integrated in future in vivo SCNT experiments 
and embryo transfers. For the production of a transgenic osteoporosis model 17 in 
vivo experiments took place so far, with an outcome of 4 fetuses and 25 piglets. 
For gaining a controllable expression of RANKL, it was necessary to establish 
double transgenic pigs to sidestep harmful effects of RANKL overexpression 
during the fetal development. First attempts to integrate both genes, tetracycline 
controlled transactivator (Tet-On) and RANKL, in a single step of cell 
transfection and SCNT, had no satisfying result. We obtained 4 fetuses and 
stillborn recloned piglets carrying both genes, but they showed only expression of 
Tet-On and it was impossible to induce RANKL overexpression. Therefore the 
strategy was changed in favor to two rounds of transfection and nuclear transfer. 
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First Tet-On transgenic piglets were established and screened for integration and 
expression. Piglet 9894 showed the best expression and severed as donor for next 
cell transfection step. These Tet-On + TARE RANKL cells were in vitro tested 
for their inducibility. Thereafter SCNT and embryo transfer of the best candidate 
were performed and they resulted in 4 pregnancies which all finished to term. One 
double transgenic piglet could be raised and will be kept until adulthood to 
establish a line of Tet-On +TARE RANKL transgenic pigs. Importantly, this 
founder animal showed inducible RANKL overexpression. Other constructs might 
be based on the existing Tet-On cell line in the future, offering an inducible 
system for a broad variety of different transgenes. Thus a functional Tet-On 
system in the pig is reported for the first time.  
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VII. ZUSAMMENFASSUNG 
Induzierbare Expression von RANKL in transgenen Schweinen unter der 
Kontrolle des Tet-On Systems 
Da es einen enormen Bedarf an transgenen Großtieren als Modelltiere für humane 
Erkrankungen gibt, wie zum Beispiel für Osteoporose, wurde die Generierung von 
transgenen Schweinen mittels somatischen Kerntransfers genauer untersucht. 
Dabei war das Ziel herauszufinden, welchen Einfluss die einzelnen Arbeitsschritte 
auf die Produktionseffizienz haben. Aus diesem Grund wurde eine statistische 
Analyse aller in vivo Kerntransfers von Anfang 2006 bis zum Juni 2010 
durchgeführt. An dem Beispiel eines RANKL transgenen Osteoporose-Models 
wurden alle nötigen Produktionsschritte dargestellt und die Schwierigkeiten und 
Vorteile des somatischen Kerntransfers beschrieben. Die insgesamt 151 in vivo 
Experimente, wobei unterschiedliche transgene Zelllinien genutzt wurden, 
resultierten in 243 Ferkeln und Feten. Statistische Analysen zeigten, dass 
Spenderzellen, die ausschließlich in unserem Labor behandelt wurden, nach 
Kerntransfer zu einer signifikant höheren Geburtsrate der trächtigen Empfänger 
führten als Spenderzellen aus anderen Laboren. Weiterhin ergab sich ein 
Zusammenhang zwischen der Anzahl übertragener Kerntransfer-Embryonen und 
der späteren Trächtigkeitsrate, Geburtsrate und der Abortrate. Je mehr Embryonen 
übertragen wurden, desto mehr Trächtigkeiten wurden erfolgreich beendet. Es 
wurde auch sichtbar, dass in unseren Versuchen eine unterschiedliche in vitro-
Kulturdauer der Kerntransfer-Embryonen von 24 bzw. 48 Stunden keinen 
signifikanten Unterschied in der Trächtigkeits- oder Geburtsrate verursachte. 
Auch für die verschiedenen Jahreszeiten konnte kein signifikanter Einfluss auf 
Trächtigkeit oder Geburt nachgewiesen werden. Es zeigte sich aber die Tendenz, 
dass im Herbst die besten Bedingungen für einen positiven Verlauf der 
Trächtigkeit herrschen und nach Embryotransfers im Sommer die höchste 
Abortrate auftritt. All diese Untersuchungsergebnisse werden zukünftig in unseren 
Arbeitsalltag integriert und der Kerntransfer und Embryotransferablauf optimiert. 
Zur Erstellung eines transgenen Osteoporosemodells wurden 17 Embryotransfers 
durchgeführt, die in 4 gewonnenen Feten und 25 geborenen Ferkeln resultierten. 
Um eine regulierbare RANKL Expression zu erhalten war es notwendig, doppelt 
transgene Schweine zu erstellen, so dass negative Nebeneffekte der RANKL 
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Überexpression während der Fetalentwicklung vermieden wurden. Die ersten 
Versuche, Tetrazyklin Transaktivator (Tet-On) und RANKL in einem einzigen 
Schritt der Zelltransfektion und des in vivo Kerntransfers zu integrieren, führte zu 
wenig befriedigenden Ergebnissen. Es wurden 4 doppelt transgene Feten und 2 
totgeborene Ferkel gewonnen, doch es konnte nur die Expression von Tet-On 
nachgewiesen werden, da die RANKL Expression nicht induzierbar war. 
Deswegen wurde die Strategie zu Gunsten von zwei Einzelschritten der 
Zelltransfektion und in vivo Kerntransfers gewechselt. Zuerst wurden Tet-On 
transgene Ferkel erstellt und auf Integration und Expression hin untersucht. Das 
Ferkel 8994 zeigte die beste Expression und seine Zellen wurden für den nächsten 
Zelltransfektionsschritt verwendet. Die daraus resultierenden Tet-On + TARE 
RANKL-Zellen wurden in vitro auf ihre Induzierbarkeit getestet. Als 
Spenderzellen für weitere in vivo Kerntransfers diente der beste Kandidat aus 
diesen Tests. Alle 4 Embryotransfers resultierten in Trächtigkeiten, die alle auch 
ausgetragen wurden. Ein doppelt transgenes Ferkel konnte aufgezogen werden, 
das zum einen nach Erreichen der Geschlechtsreife als Gründer einer transgenen 
Schweinelinie dienen wird, und im in vivo-Test eine induzierbare Expression von 
RANKL zeigte. Die regulierbaren Tet-On Zelllinien können auch für weitere 
zukünftige Konstrukte Verwendung finden, was die Möglichkeit mannigfaltiger 
genetischer Manipulation durch ein induzierbares System eröffnet. Hiermit wird 
das erste Mal von einem funktionalen und kontrollierbaren Tet-On System im 
Schwein berichtet.  
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